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Introduction and outline of thesis: 
New targeted probes for radioimaging of angiogenesis
Abstract
Angiogenesis, the formation of new blood vessels, is a multi-step process 
regulated by pro- and anti-angiogenic factors. In order to grow and metastasize, 
tumors need a constant supply of oxygen and nutrients. For their growth 
beyond the size of 1-2 mm tumors are dependent on angiogenesis. Recently, 
various new anti-cancer agents (e.g. bevacizumab, sorafenib and sunitinib) 
have become available that specifically inhibit angiogenesis in tumors. 
To evaluate the effects of these new anti-angiogenic agents it would be of 
interest to scintigraphically image the process of angiogenesis in tumors. 
Several markers have been described that are preferentially expressed on 
newly formed blood vessels in tumors (avß3 integrin, vascular endothelial 
growth factor and its receptor, prostate-specific membrane antigen) and 
in the extracellular matrix surrounding newly formed blood vessels (extra 
domain B of fibronectin, Tenascin-C, matrix metalloproteinases, Robo-4). 
Several ligands targeting these markers have been tested as radiotracers for 
imaging angiogenesis in tumors. The potential of some of these tracers such 
as radiolabeled cyclic RGD peptides and radiolabeled anti-PSMA antibodies 
has already been tested in cancer patients, while for markers such as Robo-4 
the ligand has not yet been identified. Here, the preclinical and clinical studies 
with these new tracers to image angiogenesis in tumors are reviewed.
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Introduction
Tumor-induced angiogenesis
Angiogenesis is defined as the formation of new blood vessels from existing 
ones. This process is essential if solid tumors are to grow beyond 1 to 2 
mm diameter, at which size diffusion is no longer sufficient to supply the 
tissue with oxygen and nutrients [1]. A growing tumor is able to initiate 
angiogenesis. Tumor-induced angiogenesis is a complex multistep process 
that follows a characteristic sequence of events mediated and controlled 
by growth factors, cellular receptors and adhesion molecules [2-4]. In this 
process, five phases can be distinguished: 1. endothelial cell activation,
2. basement membrane degradation, 3. endothelial cell migration, 4. 
vessel formation, and 5. angiogenic remodeling [5]. The activation of pre­
existing quiescent vessels can be triggered by hypoxia. Hypoxia induces 
the expression of hypoxia inducible factor (HIF), which binds to the hypoxic 
response element. As a result, the expression of hypoxia inducible genes, 
such as vascular endothelial growth factor (VEGF), carbonic anhydrase IX 
(CAIX), platelet derived growth factor (PDGF), transforming growth factor-a 
(TGF-a), a.o. is induced [6]. Activated endothelial cells express the dimeric 
transmembrane integrin a vß3, which interacts with extracellular matrix 
proteins (vitronectin, tenascin, fibronectin, a.o.) and regulates migration of 
the endothelial cell through the extracellular matrix during vessel formation 
[7;8]. The activated endothelial cells synthesize proteolytic enzymes, such 
as matrix metalloproteinases (MMPs), used to degrade the basement 
membrane and the extracellular matrix [9]. Initially, endothelial cells 
assemble as solid cords. Subsequently, the inner layer of endothelial cells 
undergoes apoptosis leading to the formation of the vessel lumen. Finally 
this primary, immature vasculature undergoes extensive remodeling during 
which the vessels are stabilized by pericytes and smooth muscle cells. This 
step is often incomplete in tumors resulting in the characteristic, increased 
permeability of tumor vessels.
Based on a balance between pro-angiogenic and anti-angiogenic factors, 
a tumor can stay dormant for a very long time period until the so-called 
'angiogenic switch' occurs. In most tissues tumors can only grow to a life 
threatening size if the tumor is able to trigger angiogenesis. In tissues with 
high vessel densities, tumors may also progress via angiogenesis-independent 
co-option of the pre-existent vasculature [10].
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Anti-angiogenic therapy
The initial recognition of angiogenesis being a therapeutically interesting 
process began in the area of oncology in the early 1970s, when Folkman 
and Denekamp put forward the idea that tumors are highly vascularized and 
thereby vulnerable at the level of their blood supply. In those early years, it 
was already hypothesized that the process of angiogenesis might be a target 
for therapy. It was only after the discovery of the first compounds with specific 
angiostatic effects in the early 1990s that the research field of angiogenesis 
rapidly expanded and provided an increasing body of evidence that inhibition 
of angiogenesis could attenuate tumor growth. It is estimated that currently 
more than 300 compounds are being investigated for their potential anti- 
angiogenic effect, and a large series of inhibitors of angiogenesis have shown 
great potential in the treatment of cancer in (pre)clinical studies. Three agents 
have recently been registered as cancer therapeutics:
- Bevacizumab, the humanized anti-VEGF monoclonal antibody, was 
registered for the treatment of colon, lung and breast cancer when 
used in combination with chemotherapeutics [11;12].
- Sorafenib and sunitinib, two inhibitors of the tyrosine kinase activity 
of the VEGF and PDGF receptor, were registered for the treatment of 
metastasized renal cell carcinoma [13;14].
In summary, tumor-induced angiogenesis is a multi-step process and a key 
feature of a tumor lesion that has major impact on the biologic behavior of the 
lesion. Inhibition of angiogenesis is a new cancer treatment strategy that is now 
widely investigated clinically. Researchers have begun to search for objective 
measures that indicate pharmacological responses to anti-angiogenic drugs. 
Therefore, there is a great interest in techniques to visualize angiogenesis in 
growing tumors in vivo. During the past decade several markers of angiogenesis 
have been identified and specific tracers targeting these markers have been 
developed. Here, the characteristics of these tracers are reviewed.
Markers and scintigraphic tracers of angiogenesis
Several (glyco)proteins have been identified that are specifically expressed 
on activated endothelial cells or in the extracellular matrix surrounding the 
tumor vasculature. Most of these markers have been tested as targets for 
imaging probes.
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a vß3 Integrin
Integrins are a family of glycoproteins, that function in cellular adhesion, 
migration and signal transduction. Each member of this large family consists 
of two non-covalently bound transmembrane polypeptides (a and ß). Up till 
now more than 20 different integrins have been identified. The term integrin 
is derived from the ability of these proteins to link the extracellular matrix 
proteins with the intracellular cytoskeleton [15]. The integrin avß3 binds to a 
variety of extracellular matrix proteins (e.g. vitronectin, fibrinogen, laminin, 
collagen) through their exposed Arginine-Glycine-Aspartic acid (RGD) 
amino acid sequence [16]. avß3 is minimally expressed on normal quiescent 
endothelial cells, but significantly upregulated on proliferating endothelium 
[17]. It was found that peptides and antibodies that specifically bind avß3 
induced endothelial cell apoptosis, indicating that this integrin plays a vital 
role in endothelial cell survival during angiogenesis [18].
The tripeptidic sequence, Arg-Gly-Asp (RGD), naturally present in extracellular 
matrix proteins, is the primary binding site of the avß3 integrin. Based on the 
RGD tripeptide sequence, a series of small peptides have been designed as 
ligands to target the avß3 integrin. Kessler et al. showed that particularly cyclic 
pentapeptides containing the RGD sequence have a relatively high affinity for 
the avß3 integrin. The cyclic pentapeptide Arg-Gly-Asp-D-Phe-Val (cRGDfV) 
was a 100-fold better inhibitor of cell adhesion to vitronectin than the linear 
variant and had an affinity for avß3 in the nanomolar range [19].
For the first in vivo evaluation of cyclic RGD peptides as a scintigraphic tracer, 
Haubner et al. synthesized a series of radioiodinated RGD peptides using 
cyclo(-Arg-Gly-Asp-D-Tyr-Val) as the lead compound. These peptides were 
lipophilic and were cleared via the hepatobiliary route, resulting in high 
activity concentration in liver and intestines [20]. Several compounds were 
synthesized with the aim to improve the pharmacokinetic characteristics 
of the peptides. By glycosylation with glucose [21] or galactose [22] and by 
including more hydrophilic amino acid residues in the peptides [23] a series 
of RGD peptides were developed that were eliminated almost exclusively 
via the kidneys. Evaluation of these peptides was performed in mice using 
a xenotransplanted human melanoma model (M21). Initial liver uptake of 
the glycosylated 125I-cRGDyV peptide was 10-fold lower than that of the non­
glycosylated 125I-cRGDyV (at 10 min post-injection, uptake was 22 ± 2.8 %ID/g 
and 2.6 ± 0.2%ID/g, respectively). The blood clearance of the glycosylated 
peptide was approximately threefold faster. Tumor uptake of the glycosylated 
peptide was higher at all time points. At 240 min after tracer injection, tumor 
uptake was 1.7 ± 0.5 %ID/g, whereas it was only 0.4 ± 0.2 %ID/g for the non­
glycosylated peptide.
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While most cyclic RGD-peptides are monomers, Janssen et al. were the first 
to synthesize a dimeric RGD-peptide. Two cyclic pentapeptides c(RGDfK) 
were linked via a glutamic acid residue resulting in the peptide E-[c(RGDfK)]2. 
In a xenograft mouse model, the cRGD-peptides specifically accumulated 
in avß3 expressing tumors [24]. Dimerization resulted in higher uptake, 
presumably due to the bivalent interaction with the target cell [25]. The 
same group compared the avß3 binding characteristics of monomeric, dimeric 
and tetrameric RGD peptides in vitro and in vivo. Multimerization resulted 
in enhanced affinity for avß3 in vitro. In vivo evaluation was performed in 
mice with SK-RC-52 xenografts. The monomeric, dimeric and tetrameric 
compounds all cleared rapidly from the blood. At 8 hours post-injection, 
tumor uptake of the tetramer (7.4 ± 1.1 %ID/g) was significantly higher than 
that of the monomer (2.3 ± 0.3 %ID/g) and the dimer (5.2 ± 1.2 %ID/g) [26]. 
The compound 99mTc-NC100692 is one of the few cyclic RGD peptides for SPECT 
that has been tested in patients thus far. Nineteen of 22 malignant breast 
lesions in humans (86%) could be detected by scintigraphic imaging after 
administration of 99mTc-NC100692. The use of this tracer has been proved to 
be safe and well tolerated in subjects with breast cancer, but further studies 
are warranted to assess the clinical potential [27].
In clinical practice PET has higher resolution than SPECT imaging and images 
can be accurately analyzed quantitatively [28]. The group in Munich has 
developed an 18F-labeled cyclic RGD compound using a galactose group as a 
pharmacokinetic modifier. Initial in vivo evaluation was done using the human 
melanoma M21 model. Using this model, 18F-galacto-RGD demonstrated 
receptor selective accumulation. PET imaging studies showed that non­
invasive determination of avß3 expression with radiolabeled RGD peptides 
was feasible in mice with s.c. melanomas [21;22].
DOTA-conjugated RGD peptides were also labeled with the positron emitters 
64Cu and 68Ga. Chen et al. used PEGylation and polyvalency to optimize the 
tumor targeting efficiency and pharmacokinetics of the 64Cu labeled RGD 
peptides. In lung cancer models these peptides gave high-quality lung tumor 
images due to the minimal non-specific activity accumulation in normal 
lung tissue and the heart [29]. Decristoforo et al. demonstrated that avß3 
expression in tumors could be imaged with 68Ga-galacto-RGD [30]. The much 
easier radiosynthesis compared to 18F-galacto-RGD would make it an attractive 
alternative. However, due to higher blood pool activity of 68Ga-galacto-RGD, 
18F-galacto-RGD remains superior for imaging avß3 expression. 
18F-galacto-RGD was extensively characterized in various groups of cancer 
patients. A study in nine patients showed that avß3 expression in human tumors 
can be imaged with good tumor/background ratios [31]. The compound
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cleared predominantly via the kidneys, resulting in low background activity 
in most regions of the body. The same group also studied, if 18F-galacto-RGD 
uptake in tumors correlated with avß3 expression levels. Nineteen patients 
with solid tumors were examined with PET before resection of the tumor 
lesions. SUVs and tumor/blood ratios were found to correlate significantly 
with the intensity of immunohistochemical staining and microvessel density 
[32].
VEGF and VEGF-receptors
The most prominent mediator of tumor angiogenesis is VEGF-A, usually 
referred to as VEGF [33]. The human VEGF-A gene is organized in nine 
exons, separated by eight introns and localized on chromosome 6p21.3 [34]. 
Alternative splicing results in the generation of six isoforms, having 121, 
145, 165, 183, 189 and 206 amino acids, respectively, after signal-sequence 
cleavage. VEGF165 is the most predominant isoform: it is secreted, but a 
significant portion is bound to heparin sulphate proteoglycans on the cell 
surface and in the extracellular matrix [35]. VEGF signals through the VEGF 
receptor 2 (VEGFR-2) [36].
Bevacizumab is a humanized variant of the anti-VEGF-A monoclonal antibody 
(mAb) A.4.6.1. It is directed against a common epitope encoded by exon 4, 
present on all VEGF-isoforms, and prevents interaction with VEGFR-1 and 
VEGFR-2 [37]. Nagengast et al. were the first to demonstrate non-invasive 
VEGF imaging using radiolabeled bevacizumab. They illustrated the potential 
of 89Zr-bevacizumab and 111In-bevacizumab as a specific VEGF tracer in nude 
mice with human SKOV-3 ovarian tumor xenografts [38].
Cai et al. labeled VEGFm  with 64Cu for PET imaging of VEGFR-2 expression
[39]. Small-animal PET imaging revealed rapid, specific, and prominent 
uptake of 64Cu-DOTA-VEGFm  in highly vascularized small U87MG human 
glioblastoma tumors, but significantly lower and sporadic uptake in large 
U87MG tumors.
Prostate-specific membrane antigen (PSMA)
Prostate-specific membrane antigen (PSMA) is a transmembrane protein first 
characterized in prostate cancer. The PSMA antibody, capromab pendetide, 
labeled with m In is marketed as ProstaScint, an FDA-approved antibody 
preparation for the detection of nodal metastases in prostate cancer patients
[40]. However, this antibody is directed against an intracellular epitope of 
PSMA, which is considered a suboptimal target for antibody imaging. PSMA
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was found to be expressed on the neovascular endothelium of most solid 
tumor types, while there is no expression on the endothelial cells of normal 
tissue [41].
J591 is a monoclonal antibody directed against an epitope on the extracellular 
domain of PSMA [42]. Previous studies have shown that J591 accumulated in 
metastatic prostate cancer lesions [43]. In a recent phase I trial the feasibility 
of targeting neovasculature of a wide range of adenocarcinomas using m In- 
labeled humanized J591 was investigated. Patients with melanoma and 
cancers of the breast, colon, liver and kidney were injected with m In-J591. 
In these patients (n=24) the antibody accreted in all known tumor sites. 
Seventeen of 18 (94%) patients with soft tissue disease on standard scans 
showed uptake in the soft tissues on antibody scans as did 6 of 6 patients 
with bone disease. These data show selective targeting of PSMA expressed on 
tumor endothelium [44]. m In-huJ591 has the potential to become a suitable 
tracer for imaging angiogenesis.
More recently, the first PET imaging agent for PSMA was synthesized. In 
extension of their previous work with the 11C-labeled DCMC, that binds to 
the active carboxy peptidase site of PSMA [45], Mease et al. synthesized an 
agent containing 18F; 18F-DCFBC. 18F-DCFBC was demonstrated to localize in 
PSMA-expressing tumors in mice, allowing imaging by small animal PET [46].
Extracellular matrix proteins
A few antigens in the extracellular matrix (ECM) have been identified that are 
preferentially expressed in the surroundings of newly formed blood vessels.
Extra domain B of fibronectin
Fibronectin is a large glycoprotein in the ECM. The extra-domain B (ED-B) 
of fibronectin is a sequence of 91 amino acids, identical in mice, rats and 
humans, that can be inserted into the fibronectin molecule at sites of tissue 
remodeling by alternative splicing. ED-B is specifically expressed around 
neovascular structures in tumors and other tissues undergoing angiogenesis, 
such as the endometrium in the proliferative phase and some ocular structures 
in pathological conditions, but is undetectable in the normal adult tissues 
[47]. Using phage display technology, single chain antibodies (scFv) directed 
against EDB have been isolated [48;49]. The human antibody fragment scFv 
(L19) was shown to have subnanomolar affinity for ED-B [50].
Demartis et al. showed that radioiodinated scFv (L19) selectively accumulated 
around tumoral blood vessels in a murine tumor model. Since the ED-B 
domain of fibronectin has an identical sequence in mouse and man, they
17
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suggested clinical utility for the scintigraphic detection of angiogenesis in 
vivo [51]. Two years later, it was shown by scintigraphic imaging that 123I-L19 
selectively localized in tumor lesions of aggressive lung cancer as well as in 
liver metastases of colorectal cancer patients [52]. More recently, the amino- 
acid sequence (Gly)3-Cys-Ala was inserted at the C-terminus of L19, resulting 
in the anti-ED-B scFv named AP39, which could be labeled with 99mTc. The 
data revealed the feasibility of targeting ED-B fibronectin with 99mTc labeled 
L19 in nude mice with s.c. teratocarcinoma tumors [53].
Subsequently a series of different L19 formats were constructed, including 
dimeric scFv, a human bivalent "small immunoprotein" (SIP) and a complete 
human IgG. In comparing these different formats labeled with 125I/131I, L19-SIP 
proved to be the most suitable tracer for imaging ED-B expression in tumors. 
In 2007 Rossin et al. described 76Br-L19-SIP, the first PET imaging derivative 
of L19 for imaging of neovasculature in xenograft bearing nude mice. Besides 
clear tumor targeting, 76Br-L19-SIP also showed persistent activity in blood, 
stomach and several other normal organs, most probably due to in vivo 
debromination [54].
Extra domain C of Tenascin
Tenascin is an extracellular matrix component. Tenascin-C, containing the 
extra domain C, is a splice variant of tenascin. Overexpression of this splice 
variant has been reported in high-grade astrocytomas, with a prominent 
pattern of staining around tumor neo-vasculature. In contrast, domain C was 
undetectable in normal human tissues and by immunohistochemistry and 
even at the level of Northern blot analysis [55].
Recently, Silacci et al. reported that the extra domain C is strongly expressed in 
the majority of lung cancers, with a vascular and stromal pattern of expression. 
Using antibody phage technology, they have generated a high-affinity human 
antibody fragment (G11) which was shown to selectively target tenascin-C in 
subcutaneous U87 gliomas in mice [56]. These results pave the way for the 
clinical development of the G11 antibody for imaging angiogenesis.
MMPs and MMPIs
Matrix metalloproteinases (MMPs) are a family of more than 20 extracellular 
proteins that are capable of degrading the multiple components of 
the extracellular matrix (ECM). These enzymes are expressed during 
angiogenesis and tumor progression. MMPs are normally expressed at very 
low levels. However, when active tissue remodeling occurs, MMPs are rapidly 
upregulated [57]. In epithelial tumors most of the upregulated MMPs are 
expressed by the host stromal cells [58]. MMPs are often associated with
18
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the removal of the ECM barrier to allow cancer cells and endothelial cells to 
invade the tissue. A number of MMPs are involved in angiogenesis including 
MMPs 1, 2, 3, 9 and 14.
Using phage display libraries Koivunen et al. found that CTTHWGFTLC, a 
disulfide bridged decapeptide, selectively inhibited MMP2 and MMP9 [59]. 
The radioiodinated decapeptide was evaluated as a tracer for imaging MMP2 
and MMP9 activity. However, in vivo studies demonstrated high lipophilicity 
resulting in moderate activity uptake in the tumor and high uptake in liver and 
kidneys. Furomoto et al. labeled the MMP-2 inhibitor, SAV03, with fluorine- 
18 (18F-SAV03) [60]. The biodistribution of 18F-SAV03 and its methyl ester 
derivative, 18F-SAV03M, were studied in nude mice with s.c. Ehrlich tumors. 
The tumor uptake of the methyl ester derivative was higher than that of the 
original compound 18F-SAV03.
Magic roundabout (Robo-4)
Magic roundabout (Robo-4) is the fourth recently identified member of 
the roundabout receptor family [61]. Robo-1-3 are highly expressed in the 
nervous system and are involved in axon guidance [62]. The specificity of 
Robo-4 expression, however, is unique compared with the other three 
members; it is highly expressed in embryonic vasculature, but not in the 
nervous system [63]. Robo-4 induces endothelial migration and regulates 
angiogenesis. Some reports suggest that Robo-4 is expressed exclusively in 
tumor neovascular endothelium, and currently Robo-4 is considered a highly 
specific marker of tumor endothelium [64]. The ligand of Robo-4 has not 
been identified yet. It does not bind to slit2, the common ligand of Robo-1-3 
[65]. Further studies are needed to identify the ligands and elucidate Robo-4 
mediated signaling. Based on these ligand(s) a tracer could be developed that 
can image expression of Robo-4 in tumors.
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Summary and conclusion
Clinical trials of anti-angiogenic drugs are challenging because there is no 
established method to monitor the effect of these drugs. It has been suggested 
that the maximum tolerated dose of anti-angiogenic drugs is not necessarily 
the most effective [66]. Establishing the optimal dose of an anti-angiogenic 
agent based on tumor size measurements or on time to disease progression 
may take months or years [67]. Furthermore, in patients tumors typically 
develop resistance to anti-angiogenic drugs after 6 to 12 months of treatment 
[68]. Surrogate markers of angiogenesis are considered to be useful, not only 
for the stratification of patients for treatment with anti-angiogenic drugs, but 
also to determine optimal dosing, early clinical benefit and the development 
of resistance. Biomarkers could also become essential to justify the cost of 
targeted therapies, by increasing the likelihood of benefit to a level that is 
acceptable to patients and clinicians.
An ideal marker of angiogenesis would be expressed exclusively by the 
tumor vasculature and the ideal tracer has high sensitivity and specificity for 
this marker. Numerous markers of tumor vasculature have been identified, 
but only a few radiotracers of angiogenesis have been tested clinically. The 
most extensively studied marker of angiogenesis is the integrin avß3. For this 
marker the SPECT-tracer, 99mTc-NC100692, and the PET-tracer 18F-galacto-RGD 
have been successfully tested in humans.
Other targets exclusively expressed on activated endothelial cells may 
eventually be better targets for imaging angiogenesis. Of the identified 
markers, PSMA and Robo-4 seem to be specifically expressed on tumor 
neovasculature. m In-huJ591, a monoclonal antibody directed against an 
epitope on the extracellular domain of PSMA, specifically visualized expression 
of PSMA in the neovasculature of a wide range of adenocarcinomas in 
patients.
In conclusion, a few radiotracers for imaging angiogenesis in tumors have 
been tested in humans. The role of these tracers in assessing the response to 
anti-angiogenic therapies has yet to be assessed.
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Outline of this thesis
This thesis concentrates on radionuclide imaging of tumor-induced 
angiogenesis using the anti-VEGF-A monoclonal antibody bevacizumab.
Chapter 1 is an introduction on tumor-induced angiogenesis and in this 
chapter current knowledge on radioimaging of angiogenesis is summarized.
In Chapter 2 the feasibility of scintigraphically visualizing VEGF-A expression 
was investigated in nude mice bearing subcutaneous colon carcinoma 
xenografts.
In Chapter 3 the in vivo evaluation of 89Zr-bevacizumab in nude mice with 
subcutaneous LS174T colon carcinoma xenografts is described.
In Chapter 4 it was investigated which of the VEGF-A isoforms was/were 
responsible for the accumulation of radiolabeled anti-VEGF antibody in the 
tumors.
In Chapter 5 the scintigraphic imaging of VEGF-A expression in liver metastases 
in colorectal cancer patients was investigated.
Chapter 6 describes the conclusions and future perspectives.
In Chapter 7 and 8 the results and conclusions of the studies described in this 
thesis are discussed and summarized.
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Specific imaging of VEGF-A expression with radiolabeled 
anti-VEGF monoclonal antibody
Abstract
Purpose: Vascular endothelial growth factor-A (VEGF-A) is one of the most 
important angiogenic factors. Here we studied in a nude mouse model 
whether the expression of VEGF-A in a tumor could be imaged with a 
radiolabeled anti-VEGF antibody.
Methods: The humanized anti-VEGF-A antibody A.4.6.1. (bevacizumab), 
which is reactive with all VEGF-A isoforms, was radiolabeled with 111In or with 
125I. The accumulation of the radiolabeled antibodies in VEGF-A expressing 
tumors (LS174T) in nude mice was examined in biodistribution studies and 
by gamma camera imaging.
Results: The uptake of the 111In-bevacizumab in the tumor at 3 days post­
injection was significantly higher than that of 125I-bevacizumab (19.4 ± 7.0 
%ID/g vs. 9.6 ± 3.3 %ID/g, p=0.04). Co-injection of an excess unlabeled antibody 
resulted in a significant decrease in radioactivity concentration in the tumor 
(2.9 ± 1.9 %ID/g, p=0.01), indicating VEGF-mediated antibody uptake. Highest 
uptake in the tumor was observed at relatively low antibody protein doses 
(<3 ^g) (20-25 %ID/g). VEGF-A expressing tumors could be clearly visualized 
on planar scintigraphic images from 24 h post-injection onwards.
Conclusion: VEGF-A expression in tumors can be visualized specifically with 
radiolabeled anti-VEGF-A monoclonal antibody.
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Introduction
Angiogenesis is a complex process regulated by a delicate balance between 
pro-angiogenic and anti-angiogenic cytokines and hormones. Angiogenesis is 
essential if solid tumors are to grow beyond 1 to 2 mm diameter, at which 
size diffusion is no longer sufficient to supply the tissue with oxygen and 
nutrients [1]. Vascular endothelial growth factor-A (VEGF-A) plays a central 
role in angiogenesis. A well-characterized activity of VEGF-A is promotion of 
growth of vascular endothelial cells derived from arteries, veins and even 
lymphatics [2]. It is also considered one of the main factors responsible for the 
development and maintenance of an aberrant tumor vascular network, which 
is characterized by chaotic leaky blood vessels, resulting in inefficient blood flow 
and high interstitial fluid pressure (IFP) in the tumor. This leads to a decreased 
uptake of drugs or other therapeutics in tumors [3;4]. When administered as 
single agents, anti-angiogenic drugs have produced only modest objective 
responses in clinical trials, but overall they have not yielded long-term survival 
benefits [5]. Combining anti-VEGF treatment with chemotherapy has resulted 
in an additive or synergistic anti-tumor effect, presumably by normalization of 
the tumor vasculature. The increased penetration of drugs due to reduced IFP 
throughout the tumor is thought to enhance the efficacy of chemotherapy. In 
addition, the increased level of oxygen would enhance the efficacy of radiation 
therapy and many chemotherapeutic agents [6].
Bevacizumab is a humanized variant of the anti-VEGF-A monoclonal antibody 
A.4.6.1. It binds all VEGF isoforms and thereby prevents interaction with 
the VEGF receptor tyrosine kinases VEGFR-1 and VEGFR-2 [7]. Bevacizumab 
was approved in February 2004 for the first-line treatment of metastatic 
colorectal cancer in combination with 5-fluorouracil-based chemotherapy 
[8]. In October 2006 bevacizumab was also approved for the initial systemic 
treatment of non-small cell lung cancer in combination with carboplatin and 
paclitaxel. The marked variation in functional anatomy and pathophysiology 
within human tumors and within individual patients may account for the high 
variability of responses observed in patients [9]. As a result there is an urgent 
need for reliable markers that can predict non-invasively which patients are 
most likely to respond to anti-VEGF therapy.
The aim of this study was to investigate whether VEGF-A expression in 
tumors can be visualized scintigraphically using radiolabeled bevacizumab as 
a tracer. Bevacizumab was radiolabeled and the specificity of the antibody 
localization in the VEGF-producing tumor and the feasibility of visualizing 
VEGF-expression were investigated in nude mice bearing subcutaneous 
LS174T colon carcinoma xenografts.
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Materials and Methods
Radiolabeling and quality control
Bevacizumab (Avastin®, Roche) was radiolabeled with 125I or with 111In. For 
radioiodinationtheIodogen method was applied[10]. Briefly,5^gbevacizumab 
was incubated in a iodogen-coated tube (50 ^g) with 250 ^Ci (9.25 MBq) 
125I in phosphate buffer, pH 7.4, during 10 minutes. For labeling with m In, 
the antibody was conjugated with isothiocyanato-benzyl-DTPA as described 
previously [11]. Bevacizumab-DTPA (50 ^g) was incubated with 500 ^Ci (18.5 
MBq) 111In in 0.15 M ammonium acetate buffer pH 5.5 during 30 minutes. The 
radiolabeled antibody preparations were purified by gel filtration on a PD-10 
column (Amersham Biosciences, Roosendaal, The Netherlands) and eluted 
with PBS, 0.5% BSA. The radiochemical purity (RCP) of the radiolabeled mAb 
was determined by instant thin layer chromatography (ITLC) and exceeded 
97% for all preparations used in the studies.
Tumor model
Male nude BALB/c mice, 6-8 weeks old, were used after an acclimatization 
period of 2 weeks. The mice were housed (5 per cage) in a controlled 
environment with light/dark cycle conditions (12 h light/12 h dark) and had 
free access to water and food. LS174T human colon carcinoma cells were 
grown in RPMI supplemented with 10% FCS in a humidified atmosphere with 
5% CO2. Human tumor xenografts were induced by subcutaneous inoculation 
of LS174T cells (1 x 106 cells in 0.2 ml). Approximately 14 days later, mice 
bearing 3-4 mm diameter tumors (ca. 0.2 g) were injected in the tail vein with 
radiolabeled bevacizumab. All animal experiments were approved by the 
Animal Experiment Committee of the Radboud University Nijmegen Medical 
Center and performed in accordance with local and national guidelines.
Biodistribution studies
Mice were euthanized by CO2/O2 asphyxiation and tissues (blood, muscle, 
lung, spleen, kidney, liver and small intestine) were dissected and weighed. 
The radioactivity in the tissues was measured in a gamma counter (Wizard, 
Pharmacia-LKB). Injection standards were counted simultaneously for 
correction of decay. The activity concentration present in the samples was 
calculated and expressed as %ID/g tissue.
Determining optimal radiolabel and specificity of antibody localization
Eight tumor-bearing mice were injected with 0.2 MBq (5 |^ Ci) 111In-bevacizumab 
and 0.2 MBq (5 ^Ci) 125I-bevacizumab (3 mg bevacizumab in 0.2 ml). Three
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of the eight mice were co-injected with 300 mg unlabeled bevacizumab to 
determine non-specific uptake. Biodistribution was investigated three days 
after injection of the radiolabeled antibody. The murine antibody NUH82, 
directed against the idiotope of an anti-CAIX antibody, was used as irrelevant 
control antibody in these studies [12]. Radiolabeling, quality control and 
biodistribution studies with 111In-NUH82 were performed as described for 
111In-bevacizumab.
Antibody protein dose escalation study
Seven groups of four tumor-bearing mice were injected with 0.2 MBq (5 ^Ci) 
111In-labeled bevacizumab (0.2 ml) at 7 different protein levels (1, 3, 10, 30, 
100, 300 and 1000 ^g/mouse). The biodistribution of the radiolabel in each 
group of mice was determined 3 days post-injection.
Pharmacodynamics
Three groups of five tumor-bearing mice were injected with 0.2 MBq (5 ^Ci) 
111In-bevacizumab (3 ^g bevacizumab in 0.2 ml). One, three and seven days 
after injection a group of mice was euthanized and tissues were dissected to 
determine the biodistribution of the radiolabel as described above.
Statistical analysis
Biodistribution data were analyzed using the Graphpad Prism software 
package 4.02 (San Diego, CA). Data are presented as mean values ± SD. 
Activity concentrations (%ID/g) were analyzed using the one-way analysis of 
variance (ANOVA). Differences were considered statistically significant when 
p<0.05.
Scintigraphic imaging of VEGF expression
Three tumor-bearing mice were injected intravenously with 1 MBq (25 nCi) 
111In-bevacizumab (3 ^g/mouse). Images were acquired immediately after 
injection of the radiolabeled antibody and 1, 3 and 7 days post-injection. 
For imaging, mice were anesthetized by isoflurane/O2 inhalation anesthesia 
and placed prone on a single-head gamma camera equipped with a parallel­
hole medium-energy collimator. Images (100,000 counts/image) were stored 
digitally in a 256 x 256 matrix. After acquisition of the last images, mice were 
euthanized.
Immunohistochemistry
All tissue samples obtained were fixed in 4% buffered formalin and 
embedded in paraffin according to standard histological procedures: 4
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Figure 1
A. Biodistribution of 111In-bevacizumab (3 |ag) in athymic male mice with s.c. LS174T tumors 
at 3 days post-injection (8 mice, 3 co-injected with an excess unlabeled antibody) and 
biodistribution of 111In-NUH82 (3 |ag) in athymic male mice with s.c. LS174T tumors (4 mice).
B. Biodistribution of 125I-bevacizumab (3 |ag) in athymic male mice with s.c. LS174T tumors at 3 
days post-injection (8 mice, 3 co-injected with an excess unlabeled antibody).
tissue sections were deparaffinized with xylol and rehydrated with alcohol. 
Endogenous peroxidase activity was blocked by incubation with 0.01% H2O2 
for 30 minutes followed by PBS washes. The sections were incubated with a 
monoclonal antibody against human endothelial antigen CD34 (Qbend/10, 
dilution 1:750, Neomarkers, Fremont, CA), and a rabbit polyclonal antibody 
directed to GLUT-1 (1:200, Dako, Glostrup, Denmark). After washing, primary 
antibodies were detected by sequential incubations with biotinylated 
secondary antibody (Vector, Burlingame, CA) in PBS-BSA and avidin-biotin 
peroxidase complex (Vector). Finally, the peroxidase activity was visualized 
with 3-amino-9-ethylcarbazole (ScyTek, UT) and sections were counterstained 
with hematoxylin. To demonstrate VEGF expression, tumors were subjected to 
VEGF in situ hybridization (ISH) using a digoxigenin-labeled VEGF-A antisense 
RNA probe, as described previously [13]. The corresponding sense probe was 
used as a control. Sections were visualized (x 5) by a Zeiss Axioskop 2 FS plus 
microscope (Zeiss, Jena, Germany) and photographed using a ProgRes C10 
plus digital camera (JenOptik, Jena, Germany).
RT-PCR
To further characterize VEGF-A expression in the xenografts, RNA was isolated 
from frozen tumor tissue using Trizol reagent (Life Technologies, Breda, The 
Netherlands). From 1 ^g RNA, cDNA was created using Moloney-mouse- 
leukemia virus reverse transcriptase (Promega, Leiden, The Netherlands)
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Figure 2
Biodistribution of 111In- 
bevacizumab in athymic 
male mice with s.c. 
LS174T tumors at varying 
protein dose (1-1000 
Mg/mouse) 3 days post­
injection (4 mice/group).
and PCR was performed using a VEGF-A specific primer 5'0-GCA CCC ATG 
GCA GAA GGA GGA-3'o located in exon 4 (sense) and 5'o-TCA CCG CCT CGG 
CTT GTC AC-3'o located in exon 8 (antisense), thus amplifying all isoforms 
simultaneously. A control PCR was performed for the housekeeping gene 
PBGD (porphobilinogen deaminase). PCR products were analyzed on 0.8% 
agarose gel.
Results
Effect of the radiolabel and specificity of antibody localization
The biodistribution of 111In-bevacizumab and 125I-bevacizumab 3 days 
post-injection in mice with LS174T tumors is summarized in Fig. 1. The 
concentration of 111In-bevacizumab in the tumor was 19.4 ± 7.0 % ID/g at 3 
days post-injection and was significantly higher than that of 125I-bevacizumab 
(10 ± 1.7 %ID/g, p=0.04). Co-injection of an excess unlabeled antibody (300 Mg) 
added to the injection with 111In-bevacizumab (3 Mg) resulted in a significant 
decrease in radioactivity concentration (2.9 ± 1.9 %ID/g, p=0.01), indicating 
that bevacizumab accumulation in tumors was specific. In contrast, uptake 
in none of the normal tissues analyzed was reduced significantly after co­
injection of 300 mg unlabeled antibody. To further investigate the specificity 
of the accumulation of the 111In-labeled bevacizumab in the LS174T tumors, 
the biodistribution of 111In-bevacizumab in mice with LS174T tumors was 
compared with that of the irrelevant control antibody 111In-NUH82 (Fig. 1A). 
The radioactivity concentration of 111In-NUH82 was similar in blood and 
normal tissues. Tumor uptake of 111In-NUH82 was the same as tumor uptake 
of 111In-bevacizumab after co-injection of an excess unlabeled antibody. These 
results confirmed that the uptake of the 111In-bevacizumab in LS174T tumors 
was VEGF mediated.
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Figure 3
Biodistribution of 111In- 
bevacizumab (3 |jg) in 
athymic male mice with 
s.c. LS174T tumors at 1, 3 
and 7 days post-injection 
(5 mice/group).
Antibody protein dose escalation study
The effect of the antibody dose on the biodistribution of 111In-bevacizumab 
in mice with LS174T tumors is summarized in Fig. 2. Blood level and uptake 
in normal tissues in terms of %ID/g were not affected by the antibody 
protein dose. In Fig. 2 uptake in muscle tissue is shown as an example of 
normal tissue uptake at various antibody protein dose levels. There was 
an inverse correlation between the antibody protein dose and the uptake 
of 111In-bevacizumab in the tumor. Highest tumor uptake was observed at a 
bevacizumab dose of 1-3 Mg (20-25 %ID/g). At higher protein doses tumor 
uptake was significantly lower, while at doses exceeding 100 Mg uptake in the 
tumor was lower than 3 %ID/g.
Pharmacodynamics
The biodistribution of 111In-bevacizumab at different time points is summarized 
in Fig. 3. At one, three and seven days after injection of 111In-bevacizumab (3 
Mg), uptake in the tumor was high (15-20 %ID/g), while the uptake in the 
normal tissues decreased with time. As a result, tumor-to-non-tumor uptake 
ratios increased with time. The tumor-to-blood ratio was 2.6 after 7 days, 
while at that time the tumor-to-muscle ratio exceeded 9.
Scintigraphic imaging of VEGF expression
The images acquired at several time points after injection of 111In-bevacizumab 
(3 Mg) are shown in Fig. 4. Immediately after injection (day 0) radioactivity 
was mainly present in the heart region and in the well perfused organs. The
1 day post-injection of In-111-bevacizumab (3 Mg)
I___  3 days post-injection of In-111-bevacizumab (3 Mg)
I I 5 days post-injection of In-111-bevacizumab (3 Mg)
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day 0 day 1 day 3 day 7
Figure 4: Scintigraphic images of 3 athymic male mice with s.c. LS174T tumors immediately 
after injection and at 1, 3 and 7 days post-injection of 111In-bevacizumab (25 MCi/mouse, 3 Mg/ 
mouse).
subcutaneous LS174T tumor was visualized from day 1 onwards. At 3 days 
post-injection activity had cleared substantially from the circulation and non­
target organs resulting in distinct visualization of the LS174T tumors. Highest 
contrast images were obtained at 7 days post-injection.
Immunohistochemistry
The results of the in situ hybridization in sections of the LS174T tumors are 
shown in Fig. 5A. In the LS174T tumor expression of VEGF-encoding mRNA 
was demonstrated. VEGF-A expression was found in GLUT-1 positive, hypoxic, 
regions at constant distances from blood vessels, indicating that VEGF-A 
expression in the LS174T tumor was hypoxia-mediated (Fig. 5B).
RT-PCR
RT-PCR in RNA, extracted from frozen LS174T tumor sections, revealed that 
the most prominent isoforms of VEGF-A expressed in the LS174T tumor were 
VEGF121 and VEGF165 (Fig. 5C).
Discussion
In this study specific accumulation of radiolabeled bevacizumab in VEGF-A 
expressing tumors in a mouse model of cancer was demonstrated. 
Furthermore, the 111In-labeled antibody allowed non-invasive detection of 
VEGF-A expression in this tumor model.
The biodistribution of the radiolabeled antibody determined three days 
after injection demonstrated that both 111In- and 125I-labeled bevacizumab 
localized specifically in the tumor. The fact that the concentration of the 
labeled antibody in the tumor was significantly reduced when an excess of
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2
Figure 5
A. Paraffin coupe: ISH of VEGF in a s.c. LS174T tumor. Hypoxia mediated expression of VEGF-A 
at constant distances from blood vessels.
B. Staining of GLUT-1, a marker of hypoxia. Expression in hypoxic regions in concentric circles 
around blood vessels.
C. RT-PCR on RNA, extracted from frozen LS174T tumor sections. The housekeeping gene PBGD 
was used as a control. Lane 1-3: RNA from LS174T tumor, lane 4: RNA from sarcoma used as a 
positive control, lane 5: water used as a negative control.
unlabeled bevacizumab was co-injected indicated that the major fraction of 
the uptake of the antibody in the tumor was VEGF-A mediated. Uptake in 
normal tissues was not reduced when an excess of unlabeled antibody was 
co-injected, indicating there was only non-specific uptake in these tissues. 
Recently, Nagengast et al. reported specific accumulation of 89Zr-labeled 
bevacizumab in tumor tissue in nude mice with VEGF-A expressing human 
tumor xenografts [14]. VEGF mediated tumor uptake of 111In-bevacizumab 
was further demonstrated by showing that the radioactivity concentration 
of the irrelevant antibody 111In-NUH82 was similar in all tissues and tumor 
uptake was significantly lower than that of 111In-bevacizumab (4.12 %ID/g vs 
19.35 %ID/g, p=0.0002).
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The uptake of 111In-labeled bevacizumab was significantly higher than the 
uptake of 125I-labeled bevacizumab. The lower radioactivity concentration of 
125I-bevacizumab in the tumor was most likely due to metabolization and efflux 
of the radioiodinated metabolite from the tumor. The prolonged retention of 
the 111In-label most likely occurs owing to the improved tumor retention of 
the radiolabeled metabolite [15].
In the dose escalation experiment the effect of the dose of bevacizumab 
on in vivo targeting was studied using the 111In-labeled antibody. Highest 
tumor uptake (20-25 %ID/g) was observed at a protein dose of 1-3 Mg with 
no significant difference between these two doses (p=0.26). There was an 
inverse correlation between bevacizumab dose and tumor uptake. No further 
decrease of tumor radioactivity concentration was observed at doses > 300 
Mg, indicating that protein doses of 300 and 1,000 Mg completely saturated 
tumor-associated VEGF-A in vivo. The protein dose escalation experiment 
indicated that at higher antibody protein doses a higher bevacizumab mass 
accumulated specifically in the tumor: maximally ca. 3 Mg of bevacizumab 
accumulated per gram of LS174T tumor. This indicates that per gram of tumor 
approximately (3*10-6)/150,000 = 2*10-11 moles of VEGF were targeted. 
Assuming that 1.0 g of tumor contains 109 cells, this would indicate that per 
cell maximally: (2*10-11 x 6*1023)/109 = 12,000 VEGF molecules were targeted 
in the LS174T tumor.
The pharmacodynamics experiment demonstrated that the 111In-label was 
retained in the tumor during at least 7 days. Because the uptake in the normal 
tissues decreased with time, tumor/non-tumor ratios increased with time. 
The tumor/liver ratios amounted to 3, 5 and 7 at one, three and seven days 
after injection, respectively. These results predicted that highest contrast 
images could be obtained at later time points (i.e. 7 days p.i.).
Scintigraphic imaging of VEGF-A-expression was studied with 111In-labeled 
bevacizumab in mice bearing subcutaneous LS174T tumors. The images after 
injection of 111In-labeled bevacizumab visualized the tumors from day 1 post­
injection onwards. Further studies will be performed to determine whether 
quantitative detection of VEGF-expression using radiolabeled bevacizumab 
is possible.
The human VEGF-A gene is organized in nine exons, separated by eight 
introns [16] and is localized on chromosome 6p21.3 [17]. Alternative splicing 
results in the generation of four main isoforms of 121, 165, 189 and 206 
amino acids after signal-sequence cleavage. These VEGF-A isoforms have 
different properties. VEGF121 is an acidic polypeptide that does not bind 
heparin and heparan sulphate proteoglycans (HSPGs), and is freely diffusible. 
VEGF189 and VEGF206 are highly basic, bind to HSPG with high affinity and are
40
Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody
almost completely sequestered in the extracellular matrix (ECM). VEGF165 is 
the predominant isoform [18] and has intermediate properties; it is secreted, 
but a significant portion remains bound to the cell surface and ECM [19]. 
Bevacizumab is reported to bind all VEGF-A isoforms, but it is unclear which 
isoforms are really visualized in our imaging experiment. RT-PCR analysis of 
LS174T xenografts revealed that both VEGF121 and VEGF165 were expressed 
in the LS174T tumors. Since VEGF121 is freely diffusible, this isoform is not 
expected to result in bevacizumab accumulation in the tumor. Thus, specific 
accumulation of bevacizumab in these tumors is most likely the result of 
targeting of cell surface or matrix associated VEGF165. The expression of VEGF-A 
in the LS174T tumors is comparable to the VEGF-A expression measured in 
human tumors, as reported by Roodink et al. [20].
These experiments have shown that it is possible to scintigraphically visualize 
VEGF-A expression in tumors. VEGF-A expression is regarded as a prognostic 
factor. VEGF-A levels correlate with microvascular density and predict for 
disease recurrence and decreased survival [21]. Imaging VEGF-A expression 
could provide information on prognosis and response to chemotherapy. In a 
clinical setting one would ideally select patients for a therapy based on the 
biological characteristics of their tumor in order to identify those who will 
most likely respond to the therapy. It is currently unclear whether VEGF-A 
expression can predict which patients are most likely to respond to anti-VEGF 
therapy, but the extent of VEGF-A expression in tumor lesions might be a 
parameter that can be used to select these patients non-invasively.
Conclusion
The results of the present study demonstrate that VEGF expression in tumors 
can be detected and visualized specifically with radiolabeled anti-VEGF 
mAb.
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Immuno-PET imaging of VEGF-A expression with 
89Zr-labeled bevacizumab
Abstract
Purpose: In the present study we aimed to examine the feasibility to visualize 
VEGF-A expression in tumors by immuno-PET imaging using 89Zr-bevacizumab 
as a tracer.
Methods: Eight nude mice were injected with 4.5 MBq 89Zr-bevacizumab 
via the tail vein. Three of these mice were co-injected with an excess of 
unlabeled bevacizumab to determine non-specific uptake in tissues. Images 
were acquired directly and 1, 4 and 7 days post-injection. After the last scan 
the mice were euthanized and the biodistribution of the radiolabel was 
determined.
Results: The concentration of 89Zr-bevacizumab in the LS174T tumor was 
19.7 ± 1.7 %ID/g at seven days post-injection. Co-injection of an excess of 
unlabeled antibody (300 ^g) resulted in a significantly reduced activity 
concentration in the tumor (4.12 ± 1.9 %ID/g, p<0.01), indicating that 
bevacizumab accumulation in the LS174T tumor was antigen-mediated. The 
LS174T tumor was visualized from day 1 onwards.
Conclusion: This experiment illustrates the potential of 89Zr-bevacizumab as a 
specific VEGF-tracer in nude mice with subcutaneous LS174T tumors.
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Introduction
In previous experiments we showed by gamma camera imaging that VEGF-A 
expression can be visualized with the 111In-labeled anti-VEGF-A antibody 
bevacizumab [1]. In the present study we aimed to examine the feasibility 
to visualize VEGF-A expression in tumors by immuno-PET imaging using 89Zr- 
bevacizumab as a tracer. The advantages of positron emission tomography 
(PET) over gamma camera imaging are: a higher resolution and a more 
accurate quantitative analysis of the images [2]. In the present experiments 
we studied the in vivo characteristics of 89Zr-bevacizumab in nude mice with 
subcutaneous LS174T colon carcinoma xenografts. A small animal microPET/ 
CT scanner was used for imaging.
Materials and Methods
Tumor model
All experiments were approved by the Animal Experiments Committee of the 
Radboud University Nijmegen Medical Center and performed in accordance 
with their guidelines. Male nude BALB/c mice, 6-8 weeks old, were used. The 
mice were housed (5 mice per cage) in a controlled environment with light/ 
dark cycle conditions (12 h light/12 h dark) and had free access to water and 
food. Human tumor xenografts were induced by subcutaneous inoculation 
of LS174T colon carcinoma cells (1 x 106 cells in 0.2 ml) in the left flank. 
Approximately 14 days later, mice bearing 3-4 mm diameter tumors (ca 0.2 g) 
received an intravenous injection with 89Zr-labeled bevacizumab.
89Zr-labeling of bevacizumab
The conjugation of bevacizumab (Avastin®, 25 mg/mL; Roche) with desferal 
and the subsequent labeling with 89Zr were performed as described 
previously by Verel et al. [3]. Briefly, bevacizumab was conjugated with 
N-succinyldesferrioxamine B-tetrafluorphenol with ethylene carbodiimide. 
After removal of Fe(III) by transchelation, the pre-modified antibody was 
purified on a PD-10 column (GE Healthcare Life Sciences, Woerden, The 
Netherlands). Labeling was performed with 89Zr (Cyclotron BV, Amsterdam) 
delivered as 89Zr-oxalate dissolved in oxalic acid (1.0 M, 2 GBq/^g 89Zr, 99.9% 
radionuclide purity). The 89Zr-oxalate solution (720 MBq) was adjusted to 
pH 6.7-6.9 with 1.0 M HEPES (Sigma-Aldrich) buffer. Desferal-conjugated 
bevacizumab (0.5 mg) was added and incubated for 60 min at 37 °C. The 
radiolabeled antibody preparation was purified by gel filtration on a PD-10
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column eluted with gentisic acid (5 mg/ml) in 0.9% NaCl. The radiochemical 
purity (RCP) of the radiolabeled mAb was determined by instant thin layer 
chromatography (ITLC) using silica-gel strips and 20 mM citric acid, pH 5.0, 
as mobile phase and exceeded 95% for the preparation used in this study. 
Specific activity of 89Zr-bevacizumab was 0.45 MBq/^g.
Biodistribution and imaging
Eight mice were injected with 4.5 MBq 89Zr-bevacizumab via the tail vein (10 
Mg/mouse in 0.2 ml). Three of these mice were co-injected with an excess 
of unlabeled bevacizumab (300 ^g) to determine non-specific uptake in 
tissues. Images were acquired directly and 1, 4 and 7 days post-injection. 
For imaging, mice were anesthetized by isoflurane/O2 inhalation anesthesia 
and placed prone on an animal PET/CT scanner (Inveon®, Siemens Preclinical 
Solutions, Knoxville, TN) with an intrinsic spatial resolution of 1.5 mm. 
PET-emission scans were acquired over 15 min, followed by a CT scan for 
anatomical reference (spatial resolution 113 ^m, 80 kV, 500 ^A). Scans were 
reconstructed using Inveon Acquisition Workplace software version 1.2 
(Siemens Preclinical Solutions, Knoxville, TN), using an ordered set expectation 
maximization-3D/maximum a posteriori (OSEM3D/MAP) algorithm with the 
following parameters: matrix 256 x 256 x 159, pixel size 0.43 x 0.43 x 0.8 
mm3 and a beta-value of 0.1. After the last scan the mice were euthanized 
by CO2/O2 asphyxation and tissues (blood, muscle, lung, spleen, kidney, liver
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Figure 1: Biodistribution of 89Zr-bevacizumab in athymic nude mice with s.c. LS174T tumors at 
7 days post-injection (8 mice, 3 co-injected with an excess unlabeled antibody). As a comparison 
the biodistribution of 111In-bevacizumab is shown (historic data).
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Figure 2
MicroPET images of mice with subcutaneous LS174T tumors in the left flank at several time 
points after injection of 89Zr-bevacizumab.
and small intestine) were dissected and weighed. The radioactivity in the 
tissues was measured in a gamma counter (Wallac Wizard 3", Perkin-Elmer, 
Waltham, MA). Injection standards were counted simultaneously to correct 
for decay. The activity concentration present in the samples was calculated 
and expressed as %ID/g tissue.
Results
Biodistribution
The biodistribution of 89Zr-bevacizumab in nude mice with s.c. LS174T tumors 
is summarized in Fig 1. For comparison, the biodistribution data of 111In- 
bevacizumab (historic data) [1] are shown in the same figure. The targeting 
of 89Zr-bevacizumab to the LS174T tumor was 19.7 ± 1.7 %ID/g at seven 
days post-injection. Co-injection of an excess of unlabeled antibody (300 Mg) 
resulted in significantly reduced targeting to the tumor (4.12 ± 1.9 %ID/g, 
p<0.01), indicating that bevacizumab accumulation in the LS174T tumor was 
VEGF mediated. Uptake in the normal tissues (0.5-8 %ID/g) and in the blood 
pool (10 %ID/g) was much lower and was not affected by the co-injection of 
300 Mg bevacizumab and thus was not dependent on VEGF expression. The 
targeting of 89Zr-bevacizumab to the tumor and uptake in normal tissues was 
similar to that of 111In-bevacizumab (15.0 ± 4.2 %ID/g, p>0.05).
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Figure 3
Transverse and coronal microPET/CT images of athymic mice with s.c. LS174T tumors at seven 
days post-injection of 89Zr-labeled bevacizumab: A. transverse image, B. transverse image after 
co-injection of an excess of unlabeled bevacizumab, C. coronal image, D. coronal image after 
co-injection of an excess of unlabeled bevacizumab.
MicroPET imaging
In figure 2 the PET images acquired after injection of 89Zr-labeled bevacizumab 
are shown. Directly after injection the activity was mainly observed in the 
blood pool and in the well perfused organs. The LS174T tumor was visualized 
from day 1 onwards. At day 4 89Zr-bevacizumab accumulation in the tumor
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was observed and radioactivity had cleared from the circulation and the 
normal organs, resulting in distinct visualization of the LS174T tumor. Highest 
contrast images were obtained at day 7. The microPET/CT images acquired 
at 7 days post-injection of 89Zr-bevacizumab are shown in figure 3. After co­
injection of an excess of unlabeled antibody the LS174T tumor could not 
be delineated, indicating that the uptake of 89Zr-bevacizumab was antigen­
mediated.
Discussion
We evaluated the potential of 89Zr-bevacizumab as a PET-tracer to visualize 
VEGF expression in mice with subcutaneous LS174T xenografts. The human 
colon carcinoma cell line LS174T is known to express VEGF-A [4]. The 
biodistribution experiment demonstrated that 89Zr-bevacizumab accumulated 
specifically in the LS174T tumor with a high tumor uptake of 19.7 ± 1.7 %ID/g. 
In the present study we demonstrated the feasibility of visualizing VEGF-A 
expression in nude mice bearing subcutaneous LS174T tumors by immuno- 
PET with 89Zr-bevacizumab.
Immuno-PET, i.e. PET imaging with radiolabeled monoclonal antibodies, is 
an attractive approach for imaging tumors, because it combines the high 
resolution of PET with the specificity of a monoclonal antibody. The CT 
data, obtained by the combined PET/CT modality, can be used for adequate 
anatomic localization [5].
Nagengast et al. were the first to demonstrate the potential of 89Zr-bevacizumab 
as a specific tracer of VEGF-A expression. They used nude mice human SKOV 
ovarian tumor xenografts [6]. The antibody protein dose of bevacizumab 
used in their experiments was 100 Mg per mouse. In an antibody protein dose 
escalation study, we showed that there was an inverse relationship between 
the antibody protein dose and uptake of radiolabeled bevacizumab in the 
tumor. Highest tumor uptake was observed at a bevacizumab dose of <10 
Mg (20-25 %ID/g) [1]. For that reason, we used a relatively low bevacizumab 
protein dose (10 Mg) in this experiment. This could be an explanation for the 
higher tumor uptake of 89Zr-bevacizumab in the present study: 19.7 ± 1.7 
%ID/g as compared to 7.4 ± 2.1 %ID/g in the study by Nagengast et al.
To be appropriate for immuno-PET, a positron emitter should have a half-life 
that matches with the in vivo kinetics of the antibody. Its production should be
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easy and inexpensive, and it should allow facile, efficient and stable coupling to 
monoclonal antibodies. Given these considerations bevacizumab was labeled 
with the positron emitter 89Zr. 89Zr is particularly suitable in combination 
with intact monoclonal antibodies, because its relatively long half-life 
(t1/2=78 h) allows imaging at later time points in line with optimal target to 
background ratios of intact antibodies which are obtained several days after 
injection. Another important consideration is the way of processing of the 
radionuclide in vivo. Like 111In used in our previous imaging experiments with 
bevacizumab, 89Zr is trapped intracellularly in lysosomes when the antibody is 
internalized by the target cell, a phenomenon called residualization. Being an 
internalizing antibody, imaging of bevacizumab can best be performed using 
a residualizing positron emitter [7]. Antibodies labeled with non-residualizing 
positron emitters, such as 124I, will wash out following internalization, and 
therefore the uptake of 124I-labeled bevacizumab will be lower than that of 
89Zr-bevacizumab [8].
In the studies described above radiolabeled anti-VEGF antibodies were used 
as a tracer for imaging angiogenesis. Alternatively, Cai et al. labeled VEGF121 
with 64Cu for PET imaging of VEGF receptor expression. Small animal PET 
imaging revealed rapid, specific and prominent uptake of 64Cu-DOTA-VEGF121 
in highly vascularized small U87MG human glioblastoma tumors, reaching 
14.9 ± 0.7, 16.3 ± 0.7, 16.3 ± 0.6 and 15.1 ± 0.8 %ID/g at 2, 4, 16 and 23 h 
after injection, respectively [9]. VEGF121 potentially targets the VEGF tyrosine 
kinases, VEGFR-1 and VEGFR-2. However, it should be noted that VEGFR-1 
tyrosine kinase is known to be a decoy receptor and only VEGFR-2 levels 
reflect angiogenesis.
Immuno-PET enables the confirmation of tumor targeting and the 
quantification of monoclonal antibody accumulation. Thus, in future patients 
might be selected who have the best chance to benefit from expensive 
targeted drug therapies, while treatment schedules can be adapted to improve 
treatment efficacy and/or reduce toxicity. Moreover, immuno-PET might also 
play a role in the efficient selection, characterization, and optimization of 
novel inhibitors of angiogenesis.
Conclusion
This experiment illustrates the potential of 89Zr-bevacizumab as a specific 
VEGF-tracer in nude mice with subcutaneous LS174T tumors.
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Tumor accumulation of radiolabeled bevacizumab 
due to targeting of cell and matrix associated VEGF-A 
isoforms
Abstract
Purpose: Vascular endothelial growth factor-A (VEGF-A) is one of the most 
important factors inducing angiogenesis in tumors. At least six splice variant 
isoforms of VEGF-A have been identified, each having different properties. 
Recently, we showed that radiolabeled anti-VEGF monoclonal antibody, 
bevacizumab, accumulates specifically in VEGF-A expressing tumors. Here 
we studied in a nude mouse model which VEGF isoforms are responsible for 
tumor accretion.
Methods: The humanized anti-VEGF-A antibody A.4.6.1. (bevacizumab) 
was radiolabeled with 111In. The originally VEGF-negative Mel57 tumor was 
transfected with different VEGF isoforms (VEGF121, VEGF165 and VEGF189). The 
obtained melanoma xenografts specifically expressing different VEGF isoforms 
were used in mice. The bevacizumab uptake was examined in biodistribution 
studies and by gamma camera imaging.
Results: The tumor cell line expressing VEGF121 did not show specific uptake, 
most likely as a result of the fact that this isoform is freely diffusible. Tumors 
expressing VEGF165 and VEGF189 were clearly visualized using gamma camera 
imaging.
Conclusion: The accumulation of radiolabeled bevacizumab in the tumor is 
due to interaction with VEGF-A isoforms that are associated with the tumor 
cell surface and/or the extracellular matrix. Scintigraphic imaging of the 
expression of these VEGF isoforms may thus be useful to predict response to 
anti-angiogenic therapy.
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Introduction
Tumors cannot grow beyond a size of 1 to 2 mm diameter unless new blood 
vessels are formed for oxygen and nutrient supply [1]. Angiogenesis is a 
complex process that is regulated by the actions of pro-angiogenic and anti­
angiogenic cytokines and hormones. Vascular endothelial growth factor-A 
(VEGF-A) is one of the most important pro-angiogenic growth factors. A 
well-characterized activity of VEGF-A is its ability to promote growth and 
migration of vascular endothelial cells derived from arteries, veins and even 
lymphatics [2]. VEGF-A is the best characterized member of the VEGF family 
and is thought to be the predominant and most critical regulator of the 
development of the vascular system in various tumors [3].
The human VEGF-A gene is organized in nine exons, separated by eight 
introns [4] and is localized on chromosome 6p21.3 [5]. Alternative splicing 
may result in the generation of six isoforms, having 121, 145, 165, 183, 189 
and 206 amino acids, respectively, after signal-sequence cleavage. The amino 
acids encoded by exons 1-5 and 8 are contained in all isoforms. Exon 6 and
7 encode heparin-binding domains, which influence receptor binding and 
solubility. VEGF189 and VEGF206 contain a domain encoded by exon 6 and bind 
to heparin and heparan sulphate proteoglycans (HSPGs) with high affinity 
and are almost completely sequestered in the extracellular matrix (ECM). 
VEGF165 is the most predominant isoform [6]: it contains the exon 7-encoded 
domain, but lacks exon 6 and has intermediate properties; it is secreted, 
but a significant portion is bound to HSPGs on the cell surface and ECM [7]. 
VEGF121 which lacks both exon 6 and 7 does not bind to heparin and HSPGs 
and is consequently freely diffusible [8]. We previously demonstrated in a 
brain metastases model that VEGF165 and VEGF189 are angiogenic, whereas 
VEGF121 mainly induced vasodilatation and vascular permeability. In clinical 
tumors, the 121 and 165 isoforms, and to a lesser extent VEGF189, are the 
predominant VEGF isoforms [9;10].
Bevacizumab is a humanized variant of the anti-VEGF-A monoclonal antibody 
(mAb) A.4.6.1. It is directed against a common epitope encoded by exon 4 and 
expressed on all VEGF-A isoforms, preventing interaction with the tyrosine 
kinase receptors VEGFR-1 and VEGFR-2 [11]. It has been shown that anti­
angiogenic properties of bevacizumab result in growth inhibition of human 
tumors in nude mice [12]. Bevacizumab was the first FDA-approved clinical 
agent to target tumor angiogenesis and was registered in February 2004 for 
the first-line treatment of metastatic colorectal cancer in combination with 
5-FU based chemotherapy [13]. In a recent trial, the addition of bevacizumab
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to standard chemotherapy also produced a significant survival benefit in 
patients with advanced metastatic non-small cell lung cancer [14] and it was 
approved for initial treatment of irresectable non-small cell lung cancer in 
combination with carboplatin and paclitaxel in October 2006.
The marked variation in functional anatomy and pathophysiology within 
human tumors and within individual patients may account for the high 
variability of responses observed in patients [15]. For example, in vessel dense 
tissues such as liver, tumors may profit from pre-existent vasculature thereby 
reducing the dependency on angiogenesis. Liver metastases from colorectal 
adenocarcinomas grow in three patterns with different angiogenesis and 
desmoplasia as pointed out by Vermeulen et al [16]. As a result there is an 
urgent need for reliable markers that can predict which patients are most 
likely to respond to anti-VEGF therapy.
In a previous study we showed that VEGF-A expression by LS174T colon 
tumor xenografts could be visualized by gamma camera imaging after 
intravenous injection of 111In-labeled anti-VEGF mAb [17;18]. VEGF-A 
expression in these xenografts was limited to the 121 and 165 amino acid 
variants. However, it remains unclear which isoform(s) were visualized in 
these imaging experiments. The aim of this study was to determine which 
VEGF isoforms were actually targeted. Therefore we analyzed bevacizumab 
uptake in melanoma xenografts in nude mice selectively expressing VEGF121, 
VEGF or VEGF . 121 165 189
Materials and Methods
Tumor model
All animal experiments were approved by the Animal Experiments Committee 
of the Radboud University Nijmegen Medical Center and performed in 
accordance with their guidelines. Male nude BALB/c mice, 6-8 weeks old, 
were used after an acclimatization period of 2 weeks. The mice were housed 
(5 per cage) in a controlled environment with light/dark cycle conditions (12 
h light/12 h dark) and had free access to water and food. Stable transfectants 
of the Mel57 human melanoma cell line expressing VEGF121, VEGF165 or 
VEGF189 were obtained as described previously [19]. Expression of proteins 
of the appropriate size in conditioned medium was confirmed using western 
blot, using anti-VEGF antibody A20 (Santa Cruz Biotechnology, CA, USA).
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Radiolabeling and quality control
For labeling with 111In, bevacizumab was conjugated with isothiocyanato- 
benzyl-DTPA as described previously [20]. Bevacizumab-DTPA (50 ^g) was 
incubated with 20 MBq 111In in 0.15 M ammonium acetate buffer, pH 5.5 
for 30 minutes. The radiolabeled antibody preparations were purified by 
gel filtration on a PD-10 column (Amersham Biosciences, Roosendaal, The 
Netherlands) eluted with PBS, 0.5% BSA. The radiochemical purity (RCP) of the 
radiolabeled mAb (specific activity 0.3 MBq/^g) was determined by instant 
thin layer chromatography (ITLC) and exceeded 97% for all preparations used 
in the studies.
Biodistribution and imaging experiments
Nude mice were injected subcutaneously in the left flank with 0.2 ml 
matrigel® (Becton Dickinson, Franklin Lakes, NJ) containing 4 x 105 Mel57- 
wt, Mel57-VEGF „ Mel57-VEGF or Mel57-VEGF cells (n=8 for each121 165 189
group). Approximately 14 days later, mice bearing 2-3 mm diameter tumors 
(ca. 0.1 g) received an intravenous injection (via the tail vein) of 0.2 MBq 
111In-bevacizumab (0.2 ml). Three mice from each group were co-injected 
with an excess unlabeled bevacizumab (300 ^g). Three days after injection, 
mice were euthanized by CO2/O2 asphyxiation and tissues (blood, muscle, 
lung, spleen, kidney, liver and small intestine) were dissected and weighed. 
The radioactivity in the tissues was measured in a gamma counter (Wizard, 
Pharmacia-LKB). Injection standards were counted simultaneously for 
correction of decay. The activity concentration in the samples was calculated 
and expressed as %ID/g tissue.
Scintigraphic imaging
For imaging experiments, mice with 3-6 mm diameter subcutaneous Mel57 
tumors expressing the different isoforms (n=3 in each group) were intravenously 
injected with 1 MBq 111In-bevacizumab (in 0.2 ml). Scintigraphic images were 
acquired immediately and at 1, 3 and 7 days post-injection. For imaging, mice 
were anesthetized by isoflurane/O2 inhalation anesthesia and placed prone on
Figure 1
Expression of VEGF isoforms by Mel57 
transfectants in vitro. A western blot is shown 
containing conditioned medium of Mel57 (lane 
1), Mel57-VEGF121 (lane 2), Mel57-VEGF165 
(lane 3) and Mel57-VEGF189 (lane 4). Note the 
absence of VEGF in parental Mel57 cells. Every 
isoform is secreted as a glycosylated protein, 
resulting in the doublet character.
1 2 3 4
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Figure 2
Biodistribution of 111In-bevacizumab in athymic male mice with s.c. Mel57 tumors at 3 days post­
injection (8 mice per group, 3 out of each group co-injected with an excess of 300 |jg unlabeled 
bevacizumab): A. Mel57-wt, B. Me!57-VEGFm, C. Mel57-VEGF165, D. Mel57-VEGF189.
a single-head gamma camera (Orbitor, Siemens, Hoffman, Estates IL) equipped 
with a parallel-hole medium-energy collimator. Images (100,000 counts/image) 
were stored digitally in a 256 x 256 matrix. After acquisition of the last images, 
mice were euthanized and tumors were snap frozen for further analysis.
Results
Biodistribution experiment
Expression of VEGF-A isoforms by the respective Mel57 transfectants is shown 
in Fig. 1. The different transfectants exclusively produce the transfected 
isoform. The biodistribution of 111In-bevacizumab in mice with subcutaneous 
Mel57 tumors expressing different VEGF-A isoforms is summarized in Fig. 
2A-D. Mel57 wild-type xenografts, known to express low levels of VEGF-A 
[21], showed an 111In-bevacizumab concentration of 8.6 ± 1.2 %ID/g. In the
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Mel57-wt
Mel57-VEGF121
Mel57-VEGF165
Mel57-VEGF189
Figure 3: Scintigraphic images of athymic male mice with s.c. Mel57 tumors expressing 
different VEGF isoforms immediately after injection and at 1, 3 and 7 days post-injection of 
111In-bevacizumab (1 MBq/mouse, 3 Mg/mouse).
0 1 3 7 days
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presence of an excess of unlabeled bevacizumab the tumor uptake of the 
111In-labeled antibody was reduced significantly: 3.9 ± 0.34 %ID/g, indicating 
that half of the antibody uptake was VEGF-mediated. The concentration of 
111In-bevacizumab in the Mel57-VEGF121 tumor was 20 ± 3 %ID/g. Uptake 
in the Mel57-VEGF121 tumors and normal tissues was not reduced in the 
presence of 300 Mg unlabeled antibody, indicating that 111In-bevacizumab 
accumulated only non-specifically in these tumors. The concentration of 
111In-bevacizumab in the Mel57-VEGF189 tumor was 37 ± 13 %ID/g. Mel57- 
VEGF165 tumors demonstrated an extremely high bevacizumab uptake of 64 
± 12 %ID/g resulting in a tumor-to-blood ratio as high as 7.9, 3 days post­
injection. The concentration of 111In-bevacizumab in the Mel57-VEGF165 and 
Mel57-VEGF189 tumors decreased significantly upon co-injection of an excess 
unlabeled antibody (20 %ID/g and 4 %ID/g respectively), indicating that 
the major part of bevacizumab uptake in these tumors was specific (VEGF 
mediated).
Scintigraphic imaging
The images acquired at several time points after injection are shown in Fig.
3. Immediately after injection (day 0) radioactivity was mainly present in the 
heart region and well perfused organs. At day 3 post-injection activity had 
accumulated in the VEGF r and VEGF „ positive tumors and had cleared from165 189
the circulation and non-target organs, resulting in distinct visualization of 
these tumors. Highest contrast images were obtained at 7 days post-injection. 
The Mel57 wild type tumors and the Mel57 tumors expressing VEGF121 were 
not delineated in the images acquired 3 and 7 days post-injection, confirming 
the lack of specific accumulation of the antibody in these tumors.
Discussion
We and others recently demonstrated that radiolabeled bevacizumab 
specifically accumulates in VEGF-A expressing tumors xenografted in nude 
mice [17;18]. The 111In-labeled antibody allowed detection of VEGF-A 
expression non-invasively by scintigraphic imaging. Bevacizumab is reported 
to have a high affinity for all VEGF-A isoforms, but it was unclear which 
isoforms expressed in the tumor were actually targeted and caused the 
specific accumulation in the tumor. Because previous work has shown that 
the larger isoforms of VEGF-A are more potent inducers of angiogenesis [9], 
it is important to know which VEGF-A isoform(s) are visualized during anti- 
VEGF imaging.
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To determine which of the isoforms are responsible for the specific 
bevacizumab uptake we used stable transfectants of the human melanoma 
cell line Mel57, expressing each isoform in vitro at levels of 30-100 ng/ml per 
106 cells in 48 h [9]. The parental Mel57 cell line produces minimal amounts 
of VEGF-A in vitro [21]. Consequently, Mel57 xenografts in nude mice grow 
to necrotic tumors whereas VEGF165 expression by these tumors results in 
a highly vascularized phenotype [22]. In the present study we demonstrate 
that only expression of the cell or matrix associated VEGF-A isoforms (VEGF165 
and VEGF ,„„) resulted in tumor accumulation of radiolabeled bevacizumab.189 ;
The low levels of VEGF-A produced by the parental Mel57 xenografts were 
reflected in a very low specific uptake of bevacizumab. Specificity was assessed 
by co-injection of an excess of unlabeled antibody. Highest tumor uptake 
was observed in the Mel57 tumor expressing VEGF165 (64 ± 12 %ID/g). The 
Mel57-VEGF189 tumor also showed a high and specific tumor uptake. This high 
antibody uptake is most likely due to the properties of VEGF165 and VEGF189: 
a significant portion remains bound to the cell surface and the extracellular 
matrix. Interestingly, uptake in the Mel57-VEGF121 tumors was not reduced 
when an excess of unlabeled antibody was co-injected, indicating that the 
antibody localized in these tumors non-specifically. This can be explained by 
the fact that VEGF121 is freely diffusible resulting in the formation of soluble 
VEGF-antibody immune complexes that are not retained in the tumor.
In this study, major differences in non-specific uptake of bevacizumab 
in the Mel57 variants were observed. The concentration of radiolabeled 
bevacizumab when co-injecting an excess dose of unlabeled antibody was 
relatively high in the tumors expressing the VEGF-isoforms 121 and 165: 
17.4 ± 2.23 %ID/g and 19.6 ± 3.01 %ID/g, respectively. This may be the result 
of differences in blood volume, vascular permeability and/or interstitial 
fluid pressure in the tumor xenografts as VEGF121 is reported to induce 
vasodilatation and to enhance vascular permeability. When grown in a 
brain metastasis model, Mel57 tumors that exclusively express VEGF121 are 
characterized by a relative absence of intratumoral blood vessels, whereas 
highly dilated and hyperpermeable supposedly pre-existent vessels, are 
present in a peritumoral rim. VEGF165 and VEGF189 induce the formation of 
an intratumoral neovascular bed, consisting of irregularly dilated and leaky 
vessels. This is more prominent in VEGF165 expressing tumors when compared 
with VEGF189 tumors [9]. Thus the enhanced non-specific localization in the 
VEGF121 and VEGF165 tumors may be due to enhanced vascular permeability 
which may cause enhanced extravasation of bevacizumab in this tumor.
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The localization of radiolabeled bevacizumab in mice bearing subcutaneous 
xenografted human tumors expressing particular VEGF isoforms was also 
studied by scintigraphic imaging. The tumors expressing VEGF165 and VEGF189 
were clearly visualized, whereas the tumors expressing the VEGF121 isoform 
could not be delineated. VEGF165 and VEGF189 are extracellular matrix bound 
proteins and are known to be most capable of inducing angiogenesis. Imaging 
these VEGF-isoforms may therefore be useful in selecting patients who are 
likely to respond to anti-angiogenic therapy.
However, part of the response to anti-angiogenic therapy could be due to 
reducing the interstitial fluid pressure in the tumor. VEGF121 may not be the 
main isoform responsible for angiogenesis, but this isoform is well capable 
of inducing vasodilatation and enhancing vascular permeability. This results 
in inefficient blood flow and high interstitial fluid pressure in the tumor, 
which leads to decreased uptake of drugs or other therapeutics in tumors. 
Combining anti-VEGF therapy with chemotherapy has resulted in an anti­
tumor effect, presumably by normalization of the tumor vasculature, partly 
as a result of blocking the effect of VEGF121. As described above, the tumors 
expressing the VEGF121 isoform could not be delineated.
Conclusion
This study is the first to demonstrate specific tumor localization of radiolabeled 
bevacizumab in xenografted human tumors expressing particular VEGF- 
isoforms. Tumors expressing only VEGF121 showed no specific uptake of 
radiolabeled bevacizumab, most likely as a result of the fact that this isoform 
is freely diffusible and is not retained in the tumor. Mel57-VEGF165 and Mel57- 
VEGF189 demonstrated relatively high and specific tumor uptake of the labeled 
antibody. Thus, scintigraphy with radiolabeled bevacizumab appears to allow 
in vivo visualization of the VEGF-A isoforms that are most capable of inducing 
angiogenesis and may thus be useful to predict response to anti-angiogenic 
therapy. However it should be noted, that tumors with predominantly 
VEGF121 expression will not be visualized, whereas such tumors might still be 
susceptible to bevacizumab-induced vessel normalization.
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Imaging liver metastases of colorectal cancer patients 
with radiolabeled bevacizumab: Lack of correlation 
with VEGF-A expression
Abstract
Purpose: To investigate the correlation between tumor accumulation of 
111In-bevacizumab and VEGF-A expression in patients with colorectal liver 
metastases.
Methods: Two weeks before resection of the liver metastases twelve patients 
were intravenously injected with 111In-labeled bevacizumab. Ten minutes and 
seven days after injection a whole body scan was acquired. Seven days after 
injection 3D acquisition SPECT of the liver was performed.
Results: Enhanced uptake of 111In-bevacizumab in the liver metastases was 
observed in 9 out of 12 patients. The level of antibody accumulation in these 
lesions varied considerably. There was no correlation between the level of 
111In-labeled antibody accumulation and the level of VEGF-A expression in the 
tissue as determined by in situ hybridization and ELISA.
Conclusions: In this study we investigated the correlation between tumor 
accumulation of radiolabeled bevacizumab and VEGF-A expression in patients 
with colorectal liver metastases. No clear-cut correlation between the level 
of antibody accumulation and expression of VEGF-A was found.
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Introduction
In order to grow and metastasize, tumors need a constant supply of oxygen 
en nutrients. For their growth beyond the size of 1-2 mm diameter tumors are 
dependent on angiogenesis: the formation of new blood vessels from existing 
ones [1]. Angiogenesis is a complex and dynamic process regulated by pro- 
and anti-angiogenic factors. Vascular endothelial growth factor A (VEGF-A) 
plays a pivotal role in angiogenesis. It promotes endothelial cell proliferation 
and migration and enhances the vascular permeability of tumor vessels [2]. 
VEGF-A is frequently upregulated in tumors that are subject to hypoxia, but 
genetic factors may also contribute to enhanced VEGF-A expression [3; 4]. 
Since 2004 the humanized anti-VEGF-A monoclonal antibody (mAb), 
bevacizumab, derived from the murine mAb A.4.6.1. has been approved 
for first-line treatment of patients with metastatic colorectal cancer in 
combination with 5-fluorouracil-based chemotherapy [5]. Bevacizumab binds 
all VEGF-A isoforms, which prevents interaction with the VEGF-A receptors 
VEGFR-1 and VEGFR-2 and thus inhibits VEGF mediated effects on the tumor 
vascular network [5;6].
In previous studies in murine tumor models, we and others have shown 
that radiolabeled bevacizumab specifically accumulates in VEGF expressing 
tumors and that 111In-labeled bevacizumab allowed non-invasive detection of 
VEGF-A expression [7].
In the present study we investigated the potential of 111In-labeled bevacizumab 
to image the expression of VEGF-A in liver metastases of twelve patients 
with colorectal cancer. After scintigraphic imaging the liver metastases were 
resected. The VEGF-A expression in these resected liver metastases was 
determined by in situ hybridization and ELISA.
Material and Methods
Patients and study design
After informed consent a total of 12 patients with colorectal liver metastases 
were enrolled in this single center study at the Radboud University Nijmegen 
Medical Center. The study protocol was approved by the Institutional Review 
Board of the hospital. All patients were scheduled for resection of the 
colorectal liver metastases within 6 weeks after entering the study. Primary 
tumors had been removed at least 11 weeks before inclusion.
Exclusion criteria were pregnancy, lactation, any extrahepatic metastatic 
disease and prior chemotherapy treatment. During workup for surgical
74
Imaging liver metastases of colorectal cancer patients
resection of the colorectal liver metastases a multislice CT scan of the chest 
and the abdomen was acquired on a 4-slice scanner (Somatom Volume 
Zoom, Siemens, Erlangen, Germany). In addition, a pre-operative FDG-PET 
scan was performed (Siemens ECAT Exact 47 or Siemens Biograph PET-CT 
Siemens, CTI, Knoxville, Tennessee, USA). The volume of the liver metastases 
was estimated based on the CT images using a dedicated software package 
(HepaVision, MeVis, Bremen, Germany).
Study drug
Bevacizumab (Avastin®, Roche, Basel, Switzerland) was conjugated to isothio- 
cyanatobenzyl-diethylenetriaminepentaacetic acid (DTPA) as described 
previously [8]. Kits containing 25 mg of bevacizumab-DTPA in 1.0 ml of 0.15 
M citrate buffer, pH 5.5, ready for radiolabeling were produced and stored 
at -20 °C until use. Upon referral of a patient, a kit was labeled with 200 
MBq 111In (Mallinckrodt, Petten, the Netherlands). Radiochemical purity, as 
checked by instant thin layer chromatography (ITLC), always exceeded 95%.
Imaging
Ten to fourteen days before surgical resection of the metastases, 1 mg of 
bevacizumab, labeled with 200 MBq of 111In, was intravenously injected over 
a period of 10 minutes (1 ml/min) within 1 hour after preparation.
Ten minutes and 7 days after injection of 111In-bevacizumab, a whole body 
scan was acquired using a double-headed gamma camera (Siemens Ecam, 
Hofmann Estates, IL) equipped with medium energy collimators (symmetric 
15% window over 173 and 245 keV emission peaks, scan speed 5 cm/min 
immediately after injection and 10 cm/min at day 7). Images were stored 
digitally in a 256 x 1024 matrix. Seven days after injection, 3D SPECT (single 
photon emission computed tomograph) acquisition of the liver was performed 
allowing better visualization of any uptake in liver metastases (2 x 32 views, 
50 sec per view, 128 x 128 matrix). The uptake in liver metastases was scored 
by comparing the uptake in the metastases to that in normal liver tissue. 
Uptake was scored as: 0 (equal or less uptake than surrounding normal liver 
tissue, 1 (slightly enhanced uptake), 2 (definite enhanced uptake) or 3 (clear 
hot spot in the liver).
In addition, the uptake of 111In-bevacizumab in the liver metastases was 
semi-quantitatively scored by drawing regions of interest (ROI) over the 
liver metastases and adjacent normal liver tissue on the planar images. 111In- 
bevacizumab uptake in the ROI was expressed as the percentage increased 
uptake: (uptake in tumor-uptake in normal liver)/uptake in normal liver.
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Table 1: Patient and tumor characteristics
Number of patients Number of metastases
Total 12 1 5
Male 6 2 6
Female 6 3 1
Age (years) >4 0
Mean 63.2 Mean 1.7
Median 63.5 Median 1.5
Range 50-75 Range 1-3
TNM Classification Size largest metastasis (cm)
T1 0 Mean 3.2
T2 2 Median 3.3
T3 9 Range 1.6-4.8
T4 1 Volume metastases (ml)
N0 7 Mean 11.0
N1 2 Median 9.7
N2 3 Range 1.2-37.8
M0 0
M1 12
VEGF-A plasma concentration
Prior to injection of 111In-bevacizumab a blood sample was obtained to 
determine the plasma VEGF concentration (ng/ml). Plasma samples were 
stored at -80 °C within 1 hour after venipuncture. A four-antibody sandwich 
ELISA was used, using duck anti-chicken and chicken anti-VEGF in the pre­
analyte stage and rabbit anti-VEGF and goat anti-rabbit in the post-analyte 
stage [9].
In situ hybridization
Spatial information on VEGF-A expression of all VEGF-A isoforms in tumor 
tissue was acquired by in situ hybridization on formalin-fixed, paraffin- 
embedded tissue samples of all included patients. Sections (10 ^m) were 
cut and hybridized with a digoxigenin-labeled antisense VEGF RNA probe as 
described previously [8]. A sense probe was used as control. Hybridized RNAs 
were detected using an anti-digoxygenin-alkaline-phosphatase antibody, 
which was visualized using NBT-BCIP (Nitro- Blue Tetrazolium Chloride/ 
5-Bromo-4-Chloro-3'-Indolyphosphate p-Toluidine Salt) using standard 
conditions [10].
VEGF-A levels in tumor extract
From frozen metastases, thick cryosections were cut and pooled in RIPA
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buffer (150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 1% NP-40, 
0.5% sodiumdeoxycholaat and protease-inhibitors (Cocktail, Roche, Basel, 
Switzerland) containing heparin (5U/ml) to release matrix-bound isoforms 
of VEGF-A. Sections were homogenized, incubated on ice for 20 minutes 
and centrifuged (800 x g, 20 min at 4°C) to prepare a clear lysate. Protein 
concentrations were determined by the Bradford method (Biorad, Hercules, 
CA) and VEGF-A concentrations were measured in an ELISA as described 
previously. This ELISA detects all VEGF-A isoforms [9].
Immunohistochemical analysis
Vascular density of the liver metastases was studied in tissue sections that 
were stained with an anti-CD31 monoclonal antibody (JC70A, dilution 1:40, 
Dako, Glostrup, Denmark). A peroxidase-conjugated mouse antibody against 
smooth muscle actin (a-SMA, Sigma Chemical Co. St. Louis, USA) was used 
for detection of pericytes as a measure of vessel maturation stage. To detect 
hypoxic cells in the tumor, immunostainings for GLUT-1 expression were 
performed (A3536, dilution 1:200, Dako, Glostrup, Denmark). Peritumoral 
vascular density, SMA expression and GLUT-1 expression were semi- 
quantitatively scored on a scale ranging from undetectable (-), low (±), 
moderate (+), high (++) to very high (+++).
Statistical analysis
Correlations between the scintigraphic images and the laboratory results were 
determined by Pearson's (r) and Spearman's (p) correlation coefficients.
Figure 1
A. 111In-bevacizumab scan: Scintigraphic imaging of a liver metastasis with 111In-bevacizumab,
B. 4-phase CT scan: Imaging of liver metastasis,
C. PET/CT scan: Combined FDG-PET scan and CT scan of the liver lesion.
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Patient Number
of
lesions
Volume largest 
lesion (ml)
m ln- bevacizumab 
uptake in largest 
lesion*
m ln-bevacizumab 
uptake, semi- 
quantitative score+
ISH* VEGF-A in tumor 
extract (ng/mg 
protein)
Plasma VEGF 
level (ng/ml)
CD31* a-SMA* GLUT-1*
1. 1 1.2 1 2.4 + 0.83 0.80 + +++ +++
2. 1 7.5 2 19 ++ 4.20 0.89 + ++ +++
3. 2 8.6 2 16 - NA4 0.54 ++ +++ ++
4. 3 10.8 3 55 + 2.00 1.02 ++ +++ +
5. 1 37.8 3 38 + 3.70 0.40 ++ +++ +
6. 2 24.5 1 36 - 1.70 0.24 + +++ +
7. 1 6.3 0 Not measurable - 0.54 0.47 - - +
8. 2 3.1 0 Not measurable ++ 28.3 0.25 + + ++
9. 2 7.0 1 Not measurable - 0.64 0.41 ++ ++ +
10. 2 14.9 3 37 + 0.70 0.70 +++ +++ +
11. 2 6.8 0 Not measurable NA 0.63 0.63 NA NA NA
12. 1 4.1 3 23 - 0.24 0.24 + +++ +++
* Uptake o f m ln-antibody in liver metastases: no uptake (0), slightly enhanced uptake (1), enhanced uptake (2), hot spot (3), 
+ Semi-quantitative score: (uptake tum or-uptake normal liver tissue)/(uptake normal liver tissue),
$ ISH, CD31, a-SMA, GLUT-1: undetectable (-), low (±), moderate (+), high (++), very high (+++),
NA: Not Analyzed.
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Results
Patient and tumor characteristics
Patient and tumor characteristics are listed in table 1. A total of twelve 
patients were enrolled in this study. The study population consisted of 6 
males and 6 females with a median age of 64 years (range 50-75 years). The 
mean number of metastases in the liver was 1.7 ± 0.7. Five of the 12 patients 
had a solitary liver metastasis. Six patients had two lesions and one patient 
had three lesions. The mean diameter of the largest metastasis was 3.2 ± 1.0 
cm, the mean volume of the largest liver metastases measured on CT was
11.0 ± 10.5 ml.
Scintigraphic Imaging
The 111In-labeled bevacizumab images acquired 10 minutes after injection 
showed distribution of the radiolabeled antibody in the vascular system and 
blood-rich organs such as liver and spleen. On the images 7 days after injection 
enhanced 111In-bevacizumab targeting was observed in the liver metastases 
of 9 patients. A representative example of a scintigraphic image of a patient 
with enhanced uptake of 111In-bevacizumab in the liver metastasis is shown 
in Figure 1.
Of the nine patients that showed positive imaging results, a clear hot spot 
was visible (score 3) in 4 patients, a definite increase (score 2) was observed 
in 2 patients and the uptake was slightly increased (score 1) in 3 patients 
(Table 2). The semi-quantitative score of uptake in liver metastases provided 
similar results as the visual scoring (Table 2).
Twenty liver metastases were studied in 12 patients. In all patients with 
more than one liver lesion only the largest metastasis was visible on the 
scintigraphic images. There was no significant correlation between the level 
of 111In-bevacizumab uptake in the liver lesions, as derived from the image, 
and the diameter of the largest metastasis (r=0.62, p=0.10) or the volume of 
the largest metastasis (r=0.54, p=0.17).
Blood samples
The VEGF plasma levels as measured in the blood obtained before injection 
of the 111In-bevacizumab are listed in table 2. Plasma VEGF levels ranged from
0.24 to 1.02 ng/ml. There was no correlation between the levels of VEGF in 
the plasma and the level of 111In-bevacizumab uptake in the liver metastases 
(r=0.06, p=0.89).
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Figure 2: Immunohistochemistry
Tissue samples from patient with score 1 111In-bevacizumab uptake on scintigraphic image.
A. Moderate VEGF expression with in situ hybridization (+), B. High CD31 expression (++), 
C. Very high a-SMA expression (+++), D. Moderate Glutl expression (+).
In situ hybridization
The in situ hybridization for VEGF-A on sections of the liver metastases was 
positive in 6 patients with high local levels of VEGF mRNA expression in the 
tissue samples of two of these patients (Table 2). Of these two patients, one 
had a high uptake of 111In-bevacizumab in the liver metastasis (score 3). The 
other patient did not have visible uptake of the radiolabeled antibody (score 
0). VEGF-A levels as determined by in situ hybridization correlated significantly 
with the VEGF-A levels in the tissues as determined by ELISA (Spearman's 
p=0.71 with p=0.04). The VEGF levels in plasma of these patients were 0.89 
and 0.25 ng/ml, respectively. There was no correlation between the VEGF-A 
levels in the liver metastases as determined by in situ hybridization and the 
level of VEGF in plasma or the uptake of 111In-bevacizumab in the lesion 
(Spearman's p=0.13 and 0.43 resp. with p=0.76 and 0.19 respectively).
VEGF-A levels in tumor extract
VEGF-A levels in tumor tissue extract were determined using an enzyme- 
linked immunosorbent assays. VEGF levels in tumor extracts varied from 0.54
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to 28.3 ng/mg protein. There was no correlation between the VEGF levels in 
tumor extracts and the levels of antibody accumulation on the scintigraphic 
images (p=0.22, p=0.67).
Immunohistochemical analysis
Vascular density in the liver metastases, as determined by the expression of 
CD31, was moderate (+) to high (++) for all metastases. GLUT-1 expression 
in the liver metastases (which is correlated with hypoxia) varied largely, 
ranging from low (±) to very high (+++). The expression of vessel-associated 
a-SMA was high to very high in all patients, indicating that most vessels in 
the liver metastases of these patients were mature vessels. None of these 
three immunohistochemically determined expression levels correlated with 
the 111In-bevacizumab uptake on the scintigraphic scans (Spearman's p=0.25,
0.70, 0.55 with p=0.55, 0.053, 0.16 respectively).
Discussion
The primary aim of this study was to determine the correlation between 
tumor accumulation of 111In-bevacizumab and VEGF-A expression in patients 
with colorectal liver metastases.
Bevacizumab, a humanized monoclonal antibody, inhibits the activity of 
VEGF-A on the tumor vascular network by binding and neutralizing all 
VEGF-A isoforms. In combination with intravenous 5-fluorouracil-based 
chemotherapy, bevacizumab is indicated for first- or second line treatment of 
patients with metastatic carcinoma of the colon or rectum. The response rate 
in patients treated with a combination of chemotherapy and bevacizumab 
is significantly higher (45%) than in patients treated with chemotherapy 
alone (35%). Similarly, addition of bevacizumab to the regimen of irinotecan, 
fluorouracil and leucovorin (IFL) increased the median response duration 
from 7.1 to 10.4 months [11]. However, only part of the patients treated with 
bevacizumab benefit from this therapy. Non-invasive determination of the 
VEGF-A expression in tumor lesions could potentially be used to select those 
patients who might benefit from therapy with bevacizumab. Therefore, in 
the present study imaging of the VEGF-A expression with 111In-bevacizumab 
was studied in patients with metastatic colorectal cancer.
In this study the level of VEGF-A expression was compared with the uptake 
of the radiolabeled antibody in the liver metastases. In nude mice with
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subcutaneous VEGF-A expressing human LS174T colorectal tumor xenografts 
we showed that 111In-bevacizumab allowed specific detection of VEGF-A 
expression, whereas non-relevant antibodies did not accumulate in the tumor
[12]. Intravenous injection of 111In-bevacizumab resulted in high and specific 
uptake in the tumor (20-25 %ID/g). Specific accumulation of radiolabeled 
bevacizumab in human tumor xenografts in nude mice was also reported by 
Nagengast and colleagues. Although in this study the relation between tumor 
uptake of radiolabeled antibody and VEGF expression was not analyzed [7]. 
In the present study the liver metastases were scintigraphically delineated in 9 
out of 12 patients. In this group of nine patients antibody accumulation in the 
liver varied considerably. Despite extensive efforts to accurately determine 
VEGF-A expression in the lesions, no correlation was found between VEGF-A 
expression levels in the tumor samples as determined by in situ hybridization, 
ELISA and antibody accumulation in the liver lesions.
To date at least seven splice variants of VEGF-A are known: VEGF121, VEGF145, 
VEGF165, VEGF183, VEGF189 and VEGF206. Alternative splicing of a pseudo-exon 
9 results in the generation of inactive VEGF165b variant [13]. Whereas VEGF121 
is a freely diffusible protein, VEGF189 and VEGF206 are almost completely 
sequestered in the extracellular matrix (ECM). VEGF165 (the predominant 
isoform of VEGF-A) has intermediate properties; it is secreted and a significant 
fraction is associated with the tumor cell surface and the ECM. Using mouse 
models with human VEGF-A negative MEL57 tumors, transfected with cDNA 
encoding VEGF-A specific isoforms, we recently demonstrated that the 
accumulation of the antibody in the tumor is due to interaction with VEGF-A 
isoforms that are associated with the tumor cell surface or ECM [14].
When measuring the levels of VEGF-A in tumor extracts by ELISA or in tumor 
sections by in situ hybridization all VEGF-A isoforms are measured. Since 
the freely diffusible VEGF121 expression is not visualized by scintigraphic 
imaging, this could explain the discrepancy between the levels of VEGF-A 
as determined by in situ hybridization or ELISA and the accumulation of 
radiolabeled antibody in the liver metastases visualized on the scintigraphic 
scan. Lack of bevacizumab accumulation in VEGF-A expressing lesions could 
therefore be due to the expression of the soluble isoform VEGF121. However, 
this limits the suitability of radiolabeled bevacizumab as a tracer.
In contrast, a few liver metastases without any VEGF-A expression were 
visualized. Antibody accumulation in the tumor in the absence of VEGF-A 
expression could be due to enhanced vascular permeability of tumor vessels
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in these lesions. This will result in non-specific enhanced extravasation of the 
radiolabeled antibody in the tumor, as reported first by Morrell and colleagues 
[15]. Theoretically, any IgG molecule would accumulate in these tumors.
Although no clear-cut correlation between the level of antibody accumulation 
and expression of VEGF-A was found, it would be very interesting to correlate 
the uptake of radiolabeled antibody to the clinical outcome of the patient in 
future studies.
Conclusion
In this study we investigated the correlation between tumor accumulation of 
radiolabeled bevacizumab and VEGF-A expression in patients with colorectal 
liver metastases. No clear-cut correlation between the level of antibody 
accumulation and expression of VEGF-A was found. This may be due to the 
inability to visualize the soluble VEGF121 isoform and enhanced vascular 
permeability in tumors.
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Conclusion and future perspectives
Angiogenesis, the formation of new blood vessels from existing ones, plays 
an important role in cancer growth [1]. The most prominent mediator of 
tumor angiogenesis is VEGF-A, usually referred to as VEGF [2]. VEGF signals 
through the VEGF receptor 2 (VEGFR-2) [3]. Bevacizumab is a humanized 
variant of the anti-VEGF-A monoclonal antibody (mAb) A.4.6.1. The antibody 
is directed against a common epitope encoded by exon 4, present on all VEGF 
isoforms, and prevents interaction of VEGF-A with VEGFR-1 and VEGFR-2 [4]. 
When administered as a single agent, this anti-angiogenic drug has produced 
only modest objective responses in clinical trials, but overall it has not 
yielded long-term survival benefits [5]. Combining this anti-VEGF treatment 
with chemotherapy has resulted in additive or synergistic anti-tumor effects, 
presumably by normalization of the tumor vasculature. The increased 
penetration of drugs due to the reduced interstitial fluid pressure (IFP) in 
the tumor is thought to enhance the efficacy of chemotherapy. In addition, 
the increased level of oxygen could enhance the efficacy of radiation therapy 
and several chemotherapeutic agents [6]. Bevacizumab is registered for the 
treatment of colon, lung and breast cancer when used in combination with 
chemotherapeutics [7; 8].
Clinical trials to determine the efficacy of anti-angiogenic drugs are challenging 
for various reasons. There is no established method to monitor the effect 
of these drugs and it has been suggested that the maximum tolerated dose 
of anti-angiogenic drugs may not necessarily be the most effective dose 
[6]. Conventional radiological reporting systems for new drugs rely on one­
dimensional (Response Evaluation Criteria in Solid Tumors, RECIST) or two 
dimensional (WHO criteria) tumor size measurements. Neither is well suited 
to assess the effects of anti-angiogenic agents, the principal effect of which 
is cytostasis [9]. Furthermore, in patients tumors typically develop resistance 
to anti-angiogenic drugs after 6 to 12 months of treatment [10]. Imaging 
biomarkers of angiogenesis could be useful, not only to accelerate drug 
development, but also for the stratification of patients for treatment with 
anti-angiogenic drugs, to determine optimal dosing, early clinical benefit and 
to assess resistance.
Nagengast et al. were the first to demonstrate non-invasive VEGF imaging 
using radiolabeled bevacizumab. They illustrated the potential of 89Zr- 
bevacizumab and 111In-bevacizumab as a specific VEGF tracer in nude mice 
with human SKOV-3 ovarian tumor xenografts [11]. The studies described
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in this thesis demonstrated the feasibility of specific imaging of VEGF-A 
expression using 111In-bevacizumab and 89Zr-bevacizumab in mice with s.c. 
human colon carcinoma LS174T xenografts [12]. Accumulation of radiolabeled 
bevacizumab was also demonstrated in 9 out of 12 patients with colorectal 
liver metastases, although no correlation was found between the level 
of antibody accumulation and expression of VEGF-A in the tumor lesions
[13]. This lack of correlation could be due to the inability of radiolabeled 
bevacizumab to visualize the soluble VEGF121 isoform [14] and the enhanced 
non-specific accumulation of immunoglobulins in tumors due to locally 
enhanced vascular permeability. Thus, scintigraphy and immuno-PET with 
radiolabeled bevacizumab appears to allow in vivo visualization of the VEGF-A 
isoforms that are primarily responsible for inducing angiogenesis and may 
thus be useful to predict response to anti-angiogenic therapy. However, it 
should be noted that tumors with predominantly VEGF121 expression will not 
be visualized, whereas such tumors might still be susceptible to bevacizumab- 
induced vessel normalization. On the other hand, one could hypothesize that 
blocking of VEGF121 would cause a decrease in vascular permeability, which 
may reduce drug exposure.
Yoshimoto et al. were the first to evaluate radiolabeled VEGF as a candidate 
for angiogenesis imaging [15]. They demonstrated that radioiodinated VEGF121 
is a promising tracer for this purpose. Cai et al. labeled VEGF121 with 64Cu for 
PET imaging of angiogenesis [16]. Small animal PET imaging revealed rapid, 
specific, and prominent uptake of 64Cu-DOTA-VEGF121 in highly vascularized 
small U87MG human glioblastoma tumors with high VEGFR-2 expression, 
but significantly lower and sporadic uptake in large U87MG tumors with low 
VEGFR-2 expression. VEGF121 has affinity for both VEGFR-1 and VEGFR-2, but 
only imaging of VEGFR-2 expression is related to angiogenesis, as the VEGFR-1 
tyrosine kinase is known to be a decoy receptor. Subsequently, the same 
group developed a VEGFR-2 specific PET tracer based on mutated VEGF121
[17]. The affinity of the mutant of VEGF121 for VEGFR-1 was 20-fold lower, 
while the affinity for VEGFR-2 was fully retained. They demonstrated that 
the tumor uptake of 64Cu-labeled mutant VEGF121 measured by small animal 
PET imaging was comparable to the uptake of VEGF121 and thus confirmed 
the role of VEGF as a specific tracer for imaging VEGFR-2 expression in vivo
[18]. 121
An ideal marker of angiogenesis would be expressed exclusively by the 
tumor vasculature and the ideal tracer should have a high sensitivity and 
a high specificity for this marker. Numerous markers of tumor vasculature
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have been identified, but only a few radiotracers of angiogenesis have 
been tested clinically. The most extensively studied marker of angiogenesis 
is the integrin avß3. For this marker the SPECT tracer, 99mTc-NC100692, and 
the PET-tracer, 18F-galacto-RGD, have been successfully tested in cancer 
patients. Other targets exclusively expressed on activated endothelial cells 
may eventually be better targets for imaging angiogenesis. Of the identified 
markers, prostate-specific membrane antigen (PSMA) and Robo-4 seem to be 
specifically expressed on tumor neovasculature. 111In-huJ591, a monoclonal 
antibody directed against an epitope on the extracellular domain of PSMA, 
specifically visualized expression of PSMA in the neovasculature of a wide 
range of adenocarcinomas in patients [19].
Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) has also 
been used to non-invasively assess the response to anti-angiogenic therapy. 
Transfer constants such as Ktrans, a composite of the vascular permeability 
and endothelial surface area, are reduced in patients responding to anti- 
angiogenic agents and the correlation between the magnitude of reduction 
in transfer constants and the attainment of stable disease has been reported 
[20;21]. However, the results do not indicate that changes in DCE-MRI 
parameters correlate with prolonged time to progression or death. Further 
studies evaluating this hypothesis are indicated, as are further studies refining 
the methods of DCE-MRI acquisition and analysis.
In conclusion, only a few radiotracers for imaging angiogenesis in tumors have 
been tested in humans and the role of these tracers in assessing the response 
to anti-angiogenic therapies has yet to be established. Our method of imaging 
VEGF-A expression using radiolabeled bevacizumab is clinically applicable, 
but only tumors expressing VEGF-A isoforms that are associated with the 
extracellular matrix (e.g. VEGF165, VEGF189) are visualized. Furthermore, we 
observed non-specific uptake of the radiolabeled antibody. This problem may 
be solved by using antibody fragments (e.g. Fab or F(ab')2 fragments) instead 
of intact monoclonal antibodies. These antibody fragments distribute rapidly 
throughout the body and bind to VEGF-A in the tumor, whereas the unbound 
radiolabeled fragments clear rapidly from the tumor.
There are a few other issues that need to be addressed. Firstly, does the 
presence of the target (VEGF-A) predict the response to the targeted agent 
(bevacizumab) [22]? It was demonstrated previously that the level of 
VEGF-A expression in the primary colorectal tumor is no prognostic factor 
for the response to addition of bevacizumab to the treatment of colorectal
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liver metastases [23]. However, the level of VEGF-A expression may be site 
specific in patients with metastatic disease, with decreased expression noted 
in liver metastases relative to primary tumors and abdominal metastases. 
Secondly, bevacizumab imaging may be used as a patient stratification tool, 
but how can we monitor the response to bevacizumab in our target group 
of patients with colorectal cancer? The anti-angiogenic therapy in this group 
of patients is always combined with chemotherapy. This chemotherapy 
may cause a decrease of VEGF targeting by destroying tumor cells, without 
any response to the anti-angiogenic agent bevacizumab. This would cause 
an overestimation of the therapeutic effect of bevacizumab. Furthermore, 
it is probably impossible to use this imaging method during bevacizumab 
treatment, as the therapeutic dose of bevacizumab will block the VEGF-A 
epitopes for at least a few weeks. Bevacizumab imaging may very well be 
suited for response monitoring of tyrosine kinase inhibitor (TKI) therapy 
(e.g. sorafenib, sunitinib). We recently investigated the use of 111In-labeled 
bevacizumab as a tracer to image VEGF expression in patients with renal cell 
carcinoma before and after a four week treatment with the tyrosine kinase 
inhibitor sorafenib. We observed a reduction in 111In-bevacizumab uptake in
8 out of 9 patients after sorafenib treatment. This reduced targeting was not 
caused by reduced VEGF expression.
Cooperative efforts are needed from cellular/molecular biologists to identify 
and validate molecular imaging targets and chemists/radiochemists to 
synthesize new tracers. Close partnerships between imaging scientists, 
clinicians, the pharmaceutical industry and regulatory agencies are needed 
to promote further application of novel imaging probes in the clinical 
development of new drugs.
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Angiogenesis is defined as the formation of new blood vessels from existing 
ones. Angiogenesis is essential if solid tumors are to grow beyond 1 to 2 mm, 
at which size diffusion is no longer sufficient to supply the tissue with oxygen 
and nutrients. A growing tumor is able to induce angiogenesis. Tumor- 
induced angiogenesis is a multi-step process mediated and controlled by 
growth factors, cellular receptors and adhesion molecules. The activation of 
pre-existing quiescent vessels can be triggered by hypoxia. Hypoxia induces 
the expression of the hypoxia inducible factor-1 complex (HIF-1), which binds 
to the hypoxic response element. As a result, the expression of hypoxia 
inducible genes, such as vascular endothelial growth factor (VEGF), carbonic 
anhydrase IX (CAIX), platelet derived growth factor (PDGF), transforming 
growth factor-a (TGF-a), a.o. is induced. Based on a balance between pro- 
and anti-angiogenic factors a tumor can stay dormant for a very long time 
period until the so-called 'angiogenic switch' occurs. In tissues with high 
vessel density (e.g. liver, brain) tumors may also progress via angiogenesis- 
independent co-option of the pre-existent vasculature.
Vascular endothelial growth factor-A (VEGF-A) plays a central role in 
angiogenesis. The human VEGF-A gene is organized in nine exons, separated by 
eight introns and is localized on chromosome 6p21.3. Alternative splicing may 
result in the generation of at least six isoforms, having 121, 145, 165, 183, 189 
and 206 amino acids after signal-sequence cleavage. VEGF189 and VEGF206 bind 
to heparin and heparan sulphate proteoglycans (HSPGs) with high affinity and 
are almost completely sequestered in the extracellular matrix (ECM). VEGF165 
is the most predominant isoform: it is secreted, but a significant portion is 
bound to HSPGs on the cell surface and ECM. VEGF121, the shortest version 
(lacking the sequences encoded by exon 6 and 7), does not bind to heparin and 
HSPGs and is consequently freely diffusible. Previously, it was demonstrated 
in a brain metastases model that VEGF165 and VEGF189 are angiogenic, whereas 
VEGF121 mainly induced vasodilatation and vascular permeability.
Recently, a series of new anti-cancer agents (e.g. bevacizumab, sorafenib 
and sunitinib) has become available that specifically inhibit angiogenesis in 
tumors. Bevacizumab, the humanized anti-VEGF monoclonal antibody was 
registered for the treatment of colon, lung and breast cancer when used in 
combination with chemotherapeutics. Sorafenib and sunitinib, two inhibitors 
of the tyrosine kinase activity of the VEGF and the PDGF receptor, were 
registered for the treatment of metastasized renal cell carcinoma. Recently, 
sorafenib also established a role in the treatment of patients with advanced 
hepatocellular carcinoma.
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Surrogate markers of angiogenesis are considered to be useful, not only for 
the stratification of patients for treatment with anti-angiogenic drugs, but 
also to determine optimal dosing, early clinical benefit and the development 
of resistance. Biomarkers could also become essential to justify the cost of 
targeted therapies, by increasing the likelihood of benefit to a level that is 
acceptable to both patients and clinicians.
The aim of the studies in this thesis was to investigate whether VEGF-A 
expression in tumors could be visualized using radiolabeled bevacizumab as 
a tracer in both a preclinical and clinical setting. This could be a first step in 
the development of a tool for the stratification of patients for treatment.
In Chapter 1 the current techniques for radioimaging of angiogenesis are 
summarized. An ideal marker of angiogenesis would be expressed exclusively 
by the tumor vasculature and the ideal tracer has high sensitivity and 
specificity for this marker. Numerous markers of tumor vasculature have 
been identified, but only a few radiotracers of angiogenesis have been tested 
clinically. The most extensively studied marker of angiogenesis is the integrin 
a  ß . For this marker the SPECT-tracer, 99mTc-NC100692, and the PET-tracervr 3 ' '
18F-galacto-RGD have been successfully tested in humans. Other targets 
exclusively expressed on activated endothelial cells may eventually be better 
targets for imaging angiogenesis. Of the identified markers, PSMA and Robo-4 
seem to be specifically expressed on tumor neovasculature. 111In-huJ591, a 
monoclonal antibody directed against an epitope on the extracellular domain 
of PSMA, specifically visualized expression of PSMA in the neovasculature of a 
wide range of adenocarcinomas in patients. In conclusion, a few radiotracers 
for imaging angiogenesis in tumors have been tested in humans. However, 
the role of these tracers in the treatment of cancer patients has yet to be 
assessed.
In Chapter 2 we studied in a nude mouse model whether the expression of 
VEGF-A in a tumor could be imaged with a radiolabeled anti-VEGF antibody. 
The humanized anti-VEGF-A antibody A.4.6.1. (bevacizumab, Avastin®), 
which is reactive with all VEGF-A isoforms, was radiolabeled with 111In 
or with 1251. The accumulation of the radiolabeled antibodies in VEGF-A 
expressing tumors (LS174T) in nude mice was examined in biodistribution 
studies and by gamma camera imaging. The uptake of the 111In-bevacizumab 
in the tumor at 3 days post-injection was significantly higher than that of 
125I-bevacizumab. This is most likely due to internalization, metabolization 
and subsequent efflux of the radioiodinated metabolite from the target 
cell. Co-injection of an excess of unlabeled antibody resulted in a significant
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decrease in radioactivity concentration in the tumor, indicating VEGF 
mediated antibody uptake. Highest uptake in the tumor was observed at 
relatively low antibody protein doses (<3 ^g). VEGF-A expressing tumors 
could be clearly visualized on planar scintigraphic images from 24 h post­
injection onwards. In conclusion, VEGF-A expression in tumors can be 
visualized specifically with radiolabeled anti-VEGF-A mAb in a nude mouse 
model.
In Chapter 3 we examined the feasibility of visualizing VEGF-A expression 
in tumors by immuno-PET imaging. The advantages of positron emission 
tomography (PET) over gamma camera scintigraphy are: a higher resolution 
and a more accurate quantitative analysis of the images. We evaluated the 
potential of 89Zr-bevacizumab as a VEGF-tracer in mice with subcutaneous 
LS174T xenografts. The biodistribution experiment demonstrated that 89Zr- 
bevacizumab accumulated specifically in the LS174T tumor. Thereby we 
demonstrated the feasibility of visualizing VEGF-A expression by immuno- 
PET imaging with 89Zr-bevacizumab.
Bevacizumab is reported to have a high affinity for all VEGF-A isoforms. In 
Chapter 4 we investigated which isoforms expressed in the tumor were 
actually targeted and caused the specific accumulation of the radiolabeled 
antibody in the tumor. For that purpose the VEGF-negative Mel57 tumor was 
transfected with DNA encoding different VEGF isoforms (VEGF121, VEGF165 and 
VEGF189). The obtained melanoma xenografts specifically expressing different 
VEGF isoforms were used in mice. The bevacizumab uptake was examined 
in biodistribution studies and by gamma camera imaging. The tumor cell 
line expressing VEGF121 did not show specific uptake, presumably due to 
the fact that this isoform is freely diffusible. In contrast, 111In-bevacizumab 
accumulated specifically in tumors expressing VEGF165 and VEGF189 and these 
tumors were clearly visualized by gamma camera imaging. In conclusion, the 
accumulation of radiolabeled bevacizumab in the tumor is due to interaction 
with VEGF-A isoforms that were found to be associated with the tumor cell 
surface and/or the extracellular matrix. Thus, scintigraphy with radiolabeled 
bevacizumab appears to allow in vivo visualization of the VEGF-A isoforms 
that are primarily responsible for inducing angiogenesis and may thus be 
useful to predict response to anti-angiogenic therapy. However, it should 
be noted, that tumors with predominantly VEGF121 expression will not be 
visualized, whereas such tumors might still be susceptible to bevacizumab- 
induced vessel normalization.
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To study whether it is possible to visualize the expression of VEGF-A in tumors 
in cancer patients, a study in patients with liver metastases of colorectal cancer 
was carried out. In these patients the feasibility of imaging VEGF-A with 111In- 
labeled bevacizumab was investigated as described in Chapter 5. Two weeks 
before resection of the liver metastases twelve patients were intravenously 
injected with 111In-labeled bevacizumab. Seven days after injection a 3D 
acquisition SPECT of the liver was performed. The liver metastases were 
scintigraphically delineated in 9 out of 12 patients. In this group of 9 patients 
antibody accumulation in the liver varied considerably. The VEGF-A expression in 
the lesions was determined using a series of methods. However, no correlation 
was found between VEGF-A expression levels in the tumors (as determined by 
in situ hybridization and ELISA) and antibody accumulation in the liver lesions. 
Since the freely diffusible VEGF121 expression is not visualized by scintigraphic 
imaging, this could explain the discrepancy between the levels of VEGF-A as 
determined by in situ hybridization or ELISA and the accumulation of radiolabeled 
antibody in the liver metastases visualized on the scintigraphic scan. Antibody 
accumulation in the tumor in the absence of VEGF-A expression could be due 
to enhanced vascular permeability of tumor vessels in these lesions. This will 
result in non-specific enhanced extravasation of the radiolabeled antibody 
in the tumor. In conclusion, no clear-cut correlation between the level of 
antibody accumulation and expression of VEGF-A was found. This may be due 
to the inability to visualize the soluble VEGF121 isoform and enhanced vascular 
permeability in tumors.
The studies in this thesis demonstrated the feasibility of specific scintigraphic 
and PET imaging of VEGF-A expression using 111In-bevacizumab and 89Zr- 
bevacizumab in mice with s.c. human colon carcinoma LS174T xenografts. 
Surprisingly, no correlation was found between the level of antibody 
accumulation and expression of VEGF-A in colorectal liver metastases clinically. 
This is most likely the result of the inability to visualize the soluble VEGF121 
isoform and the enhanced vascular permeability in tumors. Thus, scintigraphy 
with radiolabeled bevacizumab appears to allow in vivo visualization of the 
VEGF-A isoforms that are primarily responsible for inducing angiogenesis and 
may thus be useful to predict response to anti-angiogenic therapy. However, it 
should be noted that tumors with predominantly VEGF121 expression will not 
be visualized, whereas such tumors might still be susceptible to bevacizumab- 
induced vessel normalization.
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Angiogenese is de vorming van nieuwe bloedvaten uit reeds bestaande 
vaten. Dit proces is van belang zodra tumoren een diameter hebben groter 
dan 1-2 mm. Vanaf die grootte kunnen tumorcellen namelijk niet meer van 
voldoende zuurstof en voedingsstoffen worden voorzien door middel van 
diffusie. Een groeiende tumor kan deze angiogenese zelf in gang zetten. Dit 
leidt tot een stapsgewijs proces dat gereguleerd wordt door groeifactoren, 
receptoren en adhesie-moleculen. Hypoxie in een tumor kan angiogenese 
induceren. Hypoxie leidt namelijk tot de expressie van het 'hypoxia inducible 
factor-1' complex (HIF-1), hetgeen uiteindelijk zorgt voor de expressie van 
verschillende genen zoals VEGF (vascular endothelial growth factor), CAIX 
(carbonic anhydrase IX), PDGF (platelet derived growth factor) en TGF-a 
(tumor growth factor-a). Door een balans tussen factoren die angiogenese 
stimuleren (pro-angiogene factoren) en remmen (anti-angiogene factoren) 
kan een tumor gedurende lange tijd inactief blijven, totdat de zogenaamde 
'angiogenic switch' plaats vindt. In weefsels met een hoge vaatdichtheid 
(hersenen, lever) kunnen tumoren ook groeien door gebruik te maken van 
de reeds aanwezige vaatvoorziening (co-optie) en de tumoren zijn dan dus 
niet afhankelijk van angiogenese.
VEGF-A speelt een centrale rol in de regulatie van angiogenese. Het gen dat 
codeert voor VEGF-A bestaat uit 9 exonen en 8 intronen. Het gen kan op 
verschillende manieren afgelezen worden, hetgeen leidt tot de verschillende 
splice-varianten van VEGF, die een verschillend aantal aminozuren bevatten: 
121, 145, 165, 183, 189 en 206. De splice-varianten waarbij ook de exonen
6 en 7 afgelezen worden (VEGF189 en VEGF206) vertonen een interactie met 
componenten in de extracellulaire matrix. VEGF121, waarbij exon 6 en 7 
niet afgelezen zijn, wordt niet gebonden aan de extracellulaire matrix 
en is dus vrij oplosbaar. Voor VEGF165 wordt alleen exon 7 afgelezen en 
deze splice-variant is daardoor deels vrij oplosbaar en deels gebonden 
aan de extracellulaire matrix. Uit eerder onderzoek in een diermodel 
met hersenuitzaaiingen is gebleken dat VEGF189 en VEGF206 angiogenese 
induceren. VEGF121 daarentegen zorgt met name voor vaatverwijding en 
vaatpermeabiliteit.
Recent zijn er verschillende nieuwe medicijnen tegen kanker op de 
markt gekomen, die de angiogenese in tumoren remmen. Bevacizumab, 
een gehumaniseerd monoklonaal antilichaam tegen VEGF, is inmiddels 
geregistreerd voor de behandeling van darm-, long- en borstkanker. Sorafenib 
en sunitinib, die de activiteit van de VEGF en PDGF receptor remmen, zijn 
geregistreerd voor de behandeling van het gemetastaseerde niercelcarcinoom.
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Sorafenib heeft tevens een plaats gekregen in de behandeling van patiënten 
met gemetastaseerde levercelkanker.
Er is een grote behoefte aan markers van angiogenese, niet alleen om 
patiënten te kunnen selecteren voor de behandeling met anti-angiogene 
middelen, maar ook om de optimale dosering van deze middelen en vroege 
respons op deze middelen te bepalen en om de ontwikkeling van resistentie 
te kunnen detecteren. Tevens zouden markers van angiogenese gebruikt 
kunnen worden om de kosten van de therapie te kunnen verantwoorden 
door het vergroten van het respons percentage.
Het doel van de studies beschreven in dit proefschrift is om te bepalen of 
VEGF-A expressie in tumoren scintigrafisch kan worden afgebeeld met 
radioactief gelabeld bevacizumab. Dit hebben we in zowel een preklinisch 
model als een klinische studie onderzocht. Dit is een eerste stap in de 
ontwikkeling van een methode om patiënten te selecteren voor de 
behandeling met anti-angiogene middelen en de optimale dosering van deze 
middelen te bepalen.
In Hoofdstuk 1 worden de technieken die op dit moment voor nucleaire 
beeldvorming van angiogenese worden ontwikkeld besproken. Een ideale 
marker van angiogenese zou specifiek tot expressie moeten komen op tumor- 
bloedvaten en de ideale tracer zou een hoge sensitiviteit en specificiteit 
voor deze marker moeten hebben. Er zijn reeds verschillende markers van 
angiogenese geïdentificeerd, maar slechts een paar van de daarvoor geschikte 
radiotracers zijn klinisch getest. De meest uitgebreid bestudeerde marker van 
angiogenese is het avß3 integrine. Voor deze marker zijn de SPECT-tracer 99mTc- 
NC100692 en de PET-tracer 18F-galacto-RGD met succes in patiënten getest. 
Andere markers die exclusief tot expressie worden gebracht door geactiveerde 
endotheelcellen zouden wellicht nog beter zijn voor het in beeld brengen 
van angiogenese in tumoren. Van de markers die reeds geindentificeerd zijn, 
worden 'prostate-specific membrane antigen' (PSMA) en Robo-4 specifiek 
op tumor-endotheel tot expressie gebracht. 111In-huJ591, een monoklonaal 
antilichaam tegen een epitoop op het extracellulaire domein van PSMA, heeft 
de PSMA expressie in de bloedvaten van verschillende tumoren bij patiënten 
specifiek in beeld kunnen brengen. Samengevat zijn er zijn slechts een paar 
radioactief gelabelde tracers voor het afbeelden van angiogenese getest in 
patiënten.
In Hoofdstuk 2 hebben we onderzocht of het mogelijk was om de VEGF 
expressie in een tumor zichtbaar te maken met een radioactief gelabeld anti- 
VEGF antilichaam (bevacizumab). Het gehumaniseerde anti-VEGF antilichaam
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A.4.6.1. (Avastin®, bevacizumab) dat bindt aan alle splice-varianten van VEGF 
werd daartoe gelabeld met 111In of 125I. Muizen met tumoren die VEGF tot 
expressie brengen werden intraveneus geïnjecteerd met radioactief gelabeld 
bevacizumab. De accumulatie van bevacizumab in de tumor werd kwantitatief 
bepaald door de concentratie radioactiviteit in het tumorweefsel en in de 
organen op verschillende tijdstippen na injectie te bepalen. De opname van 
bevacizumab gelabeld met 111In, 3 dagen na injectie, was significant hoger 
dan die van 125I-gelabeld bevacizumab. Door co-injectie van een overmaat 
ongelabeld bevacizumab nam de concentratie van het radioactief gelabelde 
bevacizumab in de tumor sterk af. Dit duidt op specifieke, VEGF gemedieerde, 
opname van het gelabelde antilichaam in de tumor. De hoogste opname van 
het 111In-bevacizumab in de tumor werd bereikt na toediening van een relatief 
lage eiwitdosis (< 3 ^g) van het antilichaam. De accumulatie van radioactief 
gelabeld bevacizumab in de tumor hebben we tevens zichtbaar gemaakt met 
gebruik van een gamma camera. De tumoren die VEGF tot expressie brengen 
konden vanaf 24 uur na injectie duidelijk afgebeeld worden met de gamma 
camera. Deze studie toonde aan dat VEGF-A expressie specifiek in beeld 
gebracht kan worden met een radioactief gelabeld anti-VEGF antilichaam.
In Hoofdstuk 3 hebben we onderzocht of het ook mogelijk is om deze VEGF-A 
expressie in beeld te brengen door middel van immuno-PET imaging. De 
voordelen van positron emissie tomografie (PET) zijn een hogere resolutie 
en een nauwkeurigere kwantitatieve analyse van de verkregen beelden. We 
hebben onderzocht of zirconium-89 (89Zr, t1/2=78 uur) gelabeld bevacizumab 
geschikt is als VEGF-tracer in muizen met subcutane LS174T tumoren. Het 
experiment toonde aan dat 89Zr-bevacizumab specifiek accumuleert in de 
LS174T tumor. We hebben laten zien dat VEGF-A expressie gevisualiseerd kan 
worden door middel van immuno-PET imaging met 89Zr-bevacizumab.
Bevacizumab bindt met hoge affiniteit aan alle VEGF splice-varianten, 
maar het is onduidelijk welke splice-varianten verantwoordelijk zijn voor 
de accumulatie van 111In-gelabeld bevacizumab. Dit werd onderzocht in 
Hoofdstuk 4. Daartoe werden muizen geïnjecteerd met tumoren die specifiek 
VEGF121, VEGF165 of VEGF189 tot expressie brengen. De tumorcellijn die VEGF121 
tot expressie brengt, liet geen specifieke opname van bevacizumab zien, 
waarschijnlijk doordat deze splice-variant van VEGF vrij oplosbaar is. Er werd 
wel specifieke accumulatie van bevacizumab aangetoond in de tumoren 
die de splice-varianten tot expressie brengen die geassocieerd zijn met de 
extracellulaire matrix: VEGF r en VEGF „. Door deze isovormen zichtbaar165 189
te maken zou meer informatie verkregen kunnen worden over de mate van
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angiogenese in de tumor en wellicht over de respons op anti-angiogene 
therapie. Als kanttekening moet worden vermeld, dat tumoren die slechts 
VEGF121 tot expressie brengen niet worden afgebeeld, hoewel deze tumoren 
wel gevoelig zouden kunnen zijn voor bevacizumab, aangezien bevacizumab 
de normalisatie van het vaatstelsel zou kunnen induceren.
Om te onderzoeken of VEGF-A expressie ook in tumoren van patiënten 
gevisualiseerd kan worden, werd een studie verricht in patiënten met 
colorectale levermetastasen. In deze studie werd het afbeelden van VEGF-A 
met 111In-gelabeld bevacizumab onderzocht, hetgeen beschreven is in 
Hoofdstuk 5. Patiënten kregen 111In-gelabeld bevacizumab i.v. toegediend en
7 dagen later werd er een 3D SPECT opname van de lever gemaakt. Bij 9 van 
de 12 patiënten werd accumulatie van bevacizumab in de levermetastasen 
gezien. Er werd echter geen correlatie tussen de VEGF-A expressie in het 
tumorweefsel en accumulatie van het bevacizumab in de tumor gevonden. 
Het ontbreken van deze correlatie wordt mogelijk veroorzaakt, doordat de 
oplosbare splice-variant, VEGF121, niet bijdraagt aan de accumulatie van het 
gelabelde bevacizumab of doordat er ook zonder VEGF expressie sprake kan 
zijn van een verhoogde permeabiliteit van de bloedvaten van de metastasen, 
waardoor het 111In-bevacizumab in de tumor kan accumuleren.
De studies in dit proefschrift tonen aan dat het mogelijk is om bij muizen met 
een subcutane, humane colorectale tumor de VEGF-A expressie specifiek 
in beeld te brengen met 111In en 89Zr-gelabeld bevacizumab. Er werd echter 
geen correlatie gevonden tussen de accumulatie van het antilichaam en de 
expressie van VEGF-A bij patiënten met colorectale levermetastasen. Dit 
komt waarschijnlijk doordat de vrij oplosbare isovorm VEGF121 niet bijdraagt 
aan de accumulatie van het 111In-gelabelde bevacizumab in de tumor en door 
de verhoogde vaatpermeabiliteit in sommige van deze tumoren. Scintigrafie 
met radioactief gelabeld bevacizumab maakt het dus mogelijk om VEGF-A 
isovormen, die primair verantwoordelijk zijn voor angiogenese, in vivo te 
visualiseren. Deze methode kan gebruikt worden om de respons op anti- 
angiogene therapie te voorspellen en op deze manier patiënten te stratificeren 
voor behandeling met deze middelen. Tumoren die met name VEGF121 tot 
expressie brengen, worden echter niet afgebeeld. Deze tumoren zouden 
echter wel gevoelig kunnen zijn voor de door bevacizumab-geïnduceerde 
vaatnormalisatie.
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